

Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients

New England Journal of Medicine

385, 790-802

DOI: 10.1056/nejmoa2105911

Citation Report

#	ARTICLE	IF	CITATIONS
1	Low-molecular-weight heparin use in coronavirus disease 2019 is associated with curtailed viral persistence: a retrospective multicentre observational study. Cardiovascular Research, 2021, 117, 2807-2820.	3.8	21
2	Implementation of an Anticoagulation Practice Guideline for COVID-19 via a Clinical Decision Support System in a Large Academic Health System and Its Evaluation: Observational Study. JMIR Medical Informatics, 2021, 9, e30743.	2.6	3
3	Bleeding risk by intensity of anticoagulation in critically ill patients with COVID-19: A retrospective cohort study. Journal of Thrombosis and Haemostasis, 2021, 19, 1533-1545.	3.8	21
4	Anticoagulation in COVID-19: reaction to the ACTION trial. Lancet, The, 2021, 397, 2226-2228.	13.7	14
5	Pulmonary Thrombosis and Thromboembolism in COVID-19. Chest, 2021, 160, 1471-1480.	0.8	92
7	Heparin â€“ Messias or Verschlimmbesserung?. Journal of Thrombosis and Haemostasis, 2021, 19, 2373-2382.	3.8	8
8	The Impact of Risk-Adjusted Heparin Regimens on the Outcome of Patients with COVID-19 Infection. A Prospective Cohort Study. Viruses, 2021, 13, 1720.	3.3	9
10	Thromboembolism and Bleeding in COVID-19. J, 2021, 4, 476-485.	0.9	1
11	Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial. Lancet Respiratory Medicine,the, 2021, 9, 1387-1395.	10.7	259
12	The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic thrombocytopenia. Trends in Cardiovascular Medicine, 2022, 32, 1-9.	4.9	31
13	Use of novel antithrombotic agents for COVID-19: Systematic summary of ongoing randomized controlled trials. Journal of Thrombosis and Haemostasis, 2021, 19, 3080-3089.	3.8	13
14	Coronavirus Disease-2019 and Heart Failure: A Scientific Statement From the Heart Failure Society of America. Journal of Cardiac Failure, 2022, 28, 93-112.	1.7	15
15	Prophylactic versus therapeutic anticoagulation for survival of patients with COVID-19 on steroid. Journal of Thrombosis and Thrombolysis, 2021, , 1.	2.1	5
16	Exogenous pulmonary surfactant in COVID-19 ARDS. The similarities to neonatal RDS suggest a new scenario for an â€“oldâ€™ strategy. BMJ Open Respiratory Research, 2021, 8, e000867.	3.0	17
17	Cardiovascular implications of the COVID-19 pandemic. Journal of Cardiology, 2022, 79, 460-467.	1.9	7
18	Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 677-686.	3.0	45
19	Efficacy of COVID-19 Treatments: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. Frontiers in Public Health, 2021, 9, 729559.	2.7	27
20	Heparin-induced thrombocytopenia in patients with COVID-19: a systematic review and meta-analysis. Blood Advances, 2021, 5, 4521-4534.	5.2	19

#	ARTICLE	IF	CITATIONS
21	A hitchhiker's guide through the COVID-19 galaxy. <i>Clinical Immunology</i> , 2021, 232, 108849.	3.2	3
22	Study of Alteplase for Respiratory Failure in SARS-CoV-2 COVID-19. <i>Chest</i> , 2022, 161, 710-727.	0.8	36
23	Emerging and Established Histological Techniques for the Analysis of Thrombosis in COVID-19 Lungs. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 745906.	2.4	1
24	The Cross-Talk between Thrombosis and Inflammatory Storm in Acute and Long-COVID-19: Therapeutic Targets and Clinical Cases. <i>Viruses</i> , 2021, 13, 1904.	3.3	24
26	Treatments Associated with Lower Mortality among Critically Ill COVID-19 Patients: A Retrospective Cohort Study. <i>Anesthesiology</i> , 2021, 135, 1076-1090.	2.5	3
27	Outpatient and inpatient anticoagulation therapy and the risk for hospital admission and death among COVID-19 patients. <i>EClinicalMedicine</i> , 2021, 41, 101139.	7.1	19
28	Anticoagulation is the answer in treating noncritical COVID-19 patients. <i>Open Medicine (Poland)</i> , 2021, 16, 1486-1492.	1.3	4
29	Comprehensive Review of Cardiovascular Complications of Coronavirus Disease 2019 and Beneficial Treatments. <i>Cardiology in Review</i> , 2022, 30, 145-157.	1.4	11
30	Antithrombotic Therapy for Outpatients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1685.	7.4	3
32	Impact of major bleeding and thrombosis on 180-day survival in patients with severe COVID-19 supported with veno-venous extracorporeal membrane oxygenation in the United Kingdom: a multicentre observational study. <i>British Journal of Haematology</i> , 2022, 196, 566-576.	2.5	27
33	Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1690.	7.4	169
34	Stroke Prevention After Cryptogenic Stroke. <i>Current Cardiology Reports</i> , 2021, 23, 174.	2.9	9
35	Therapeutic versus Prophylactic Bempiparin in Hospitalized Patients with Nonsevere COVID-19 Pneumonia (BEMICOP Study): An Open-Label, Multicenter, Randomized, Controlled Trial. <i>Thrombosis and Haemostasis</i> , 2022, 122, 295-299.	3.4	40
36	Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. <i>BMJ</i> , The, 2021, 375, n2400.	6.0	250
37	The Value of Thromboelastography (TEG) in COVID-19 Critical Illness as Illustrated by a Case Series. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2022, 36, 2536-2543.	1.3	4
38	Antiplatelet therapy and outcome in COVID-19: the Health Outcome Predictive Evaluation Registry. <i>Heart</i> , 2022, 108, 130-136.	2.9	49
39	What went wrong: A reckoning of Canada's contributions to evidence-based medicine through clinical trials during the COVID-19 pandemic. <i>Jammi</i> , 2021, 6, 241-244.	0.5	2
40	Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1635-1654.	2.8	42

#	ARTICLE	IF	CITATIONS
41	Complications of Critical COVID-19. Chest, 2022, 161, 989-998.	0.8	14
42	Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19. JAMA Internal Medicine, 2021, 181, 1612.	5.1	326
43	<scp>COVID</scp>â€19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2021, 23, 1806-1818.	7.1	32
44	Age-adjusted D-dimer cutoffs to guide anticoagulation in COVID-19 â€ Authors' reply. Lancet, The, 2021, 398, 1304.	13.7	0
45	Hypercholesterolemia and COVID-19: Statins for Lowering the Risk of Venous Thromboembolism. Frontiers in Cardiovascular Medicine, 2021, 8, 711923.	2.4	2
47	Anticoagulant Therapy in Patients Hospitalized With COVID-19. JAMA Internal Medicine, 2021, 181, 1621.	5.1	11
48	Role of neutrophils, platelets, and extracellular vesicles and their interactions in COVIDâ€19â€associated thrombopathy. Journal of Thrombosis and Haemostasis, 2022, 20, 17-31.	3.8	45
49	Glucocorticoid Dose in COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 1801.	7.4	8
50	Pre-admission acetylsalicylic acid therapy and impact on in-hospital outcome in COVID-19 patients: The ASA-CARE study. International Journal of Cardiology, 2021, 344, 240-245.	1.7	17
51	PICO Questions and DELPHI Methodology for the Management of Venous Thromboembolism Associated with COVID-19. Viruses, 2021, 13, 2128.	3.3	4
52	Combined anticoagulant and antiplatelet therapy is associated with an improved outcome in hospitalised patients with COVID-19: a propensity matched cohort study. Open Heart, 2021, 8, e001785.	2.3	18
53	Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 1703.	7.4	186
54	Pre-admission anticoagulant therapy and mortality in hospitalized COVID-19 patients: A retrospective cohort study. Thrombosis Research, 2021, 208, 35-38.	1.7	1
55	Risk of symptomatic venous thromboembolism in mild and moderate COVID-19: A comparison of two prospective European cohorts. Thrombosis Research, 2021, 208, 4-10.	1.7	14
56	SOFA Score as a Reliable Tool to Detect High Risk for Venous Thrombosis in Patients With Critical Stage SARS-CoV-2. Frontiers in Cardiovascular Medicine, 2021, 8, 729298.	2.4	3
57	Caring for Hospitalized COVID-19 Patients: From Hypes and Hopes to Doing the Simple Things First. American Journal of Tropical Medicine and Hygiene, 2021, , .	1.4	1
58	Significance of MPV, RDW and PDW with the Severity and Mortality of COVID-19 and Effects of Acetylsalicylic Acid Use. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110488.	1.7	9
60	Dilemma of Anticoagulation Therapy in Mild or Asymptomatic COVID-19 Cases. Cureus, 2021, 13, e19291.	0.5	2

#	ARTICLE	IF	CITATIONS
61	Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial. <i>BMJ, The</i> , 2021, 375, e068060.	6.0	52
62	Host-modifying drugs against <scp>COVID</scp>â€19: some successes, but not yet the breakthrough. <i>Environmental Microbiology</i> , 2021, 23, 7257-7270.	3.8	0
63	Clinical Practice in COVID-19: the most frequently asked questions to Infectious Diseases Specialists. <i>Brazilian Journal of Infectious Diseases</i> , 2021, 25, 101648.	0.6	1
64	Pathogenic Basis of Thromboinflammation and Endothelial Injury in COVID-19: Current Findings and Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12081.	4.1	21
65	COVID-19 associated coagulopathy: Mechanisms and host-directed treatment. <i>American Journal of the Medical Sciences</i> , 2022, 363, 465-475.	1.1	16
66	COVID-19 critical illness in pregnancy. <i>Obstetric Medicine</i> , 2022, 15, 220-224.	1.1	3
67	Clinical practice guideline: Recommendations on the in-hospital treatment of patients with COVID-19. <i>Deutsches A&#x0308;rztblatt International</i> , 2021, , .	0.9	15
68	A Population-Based Registry Analysis on Hospitalized COVID-19 Patients with Previous Cardiovascular Disease: Clinical Profile, Treatment, and Predictors of Death. <i>Journal of Cardiovascular Development and Disease</i> , 2021, 8, 167.	1.6	2
69	Learning in times of stress: Lessons from COVID-19 that will last throughout this century. <i>European Journal of Internal Medicine</i> , 2021, , .	2.2	1
70	Mortality Reduction Associated with Coexistent Antithrombotic Use in Nursing Home Residents with COVID-19. <i>Journal of the American Medical Directors Association</i> , 2022, 23, 440-441.	2.5	1
71	Arterial and Venous Thrombosis Complicated in COVID-19: A Retrospective Single Center Analysis in Japan. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 767074.	2.4	20
72	Therapeutic Anticoagulation with Heparin in Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 385, 2013-2014.	27.0	1
73	ESCMID COVID-19 living guidelines: drug treatment and clinical management. <i>Clinical Microbiology and Infection</i> , 2022, 28, 222-238.	6.0	103
74	Immune-Mediated Glycocalyx Remodeling in Hospitalized COVID-19 Patients. <i>Cardiovascular Drugs and Therapy</i> , 2023, 37, 307-313.	2.6	12
75	Ethical challenges of prospective clinical trials during the COVID-19 pandemic. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 549-554.	4.4	1
76	Incidence and effects of deep vein thrombosis on the outcome of patients with coronavirus disease 2019 infection. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2022, 10, 803-810.	1.6	5
77	Predictors and outcomes of respiratory failure among lung transplant patients with COVIDâ€19. <i>Clinical Transplantation</i> , 2022, 36, e14540.	1.6	4
78	Intermediate-to-therapeutic versus prophylactic anticoagulation for coagulopathy in hospitalized COVID-19 patients: a systemic review and meta-analysis. <i>Thrombosis Journal</i> , 2021, 19, 91.	2.1	12

#	ARTICLE	IF	CITATIONS
79	Therapeutic-dose heparin should integrate the standard of care of moderately ill patients with COVID-19 admitted to hospital. <i>European Heart Journal</i> , 2022, 43, 365-366.	2.2	0
80	Novel Coronavirus Infection (COVID-19) Related Thrombotic and Bleeding Complications in Critically Ill Patients: Experience from an Academic Medical Center. <i>Journal of Clinical Medicine</i> , 2021, 10, 5652.	2.4	2
81	The relationship between COVID-19 infection and intracranial hemorrhage: A systematic review. <i>Brain Hemorrhages</i> , 2021, 2, 141-150.	1.0	26
82	The effect of higher-intensity dosing of anticoagulation on the clinical outcomes in hospitalized patients with COVID-19: A meta-analysis of randomized controlled trials. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 257-265.	1.7	18
83	Thrombosis and Bleeding After Implementation of an Intermediate-Dose Prophylactic Anticoagulation Protocol in ICU Patients With COVID-19: A Multicenter Screening Study. <i>Journal of Intensive Care Medicine</i> , 2021, , 088506662110519.	2.8	3
84	Validation of a Prognostic Score to Identify Hospitalized Patients with COVID-19 at Increased Risk for Bleeding. <i>Viruses</i> , 2021, 13, 2278.	3.3	10
85	Anticoagulant therapy for COVID-19: What we have learned and what are the unanswered questions?. <i>European Journal of Internal Medicine</i> , 2022, 96, 13-16.	2.2	9
86	2021 Focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation. <i>Journal of Arrhythmia</i> , 2021, 37, 1389-1426.	1.2	38
87	Daily Monitoring of D-Dimer Allows Outcomes Prediction in COVID-19. <i>TH Open</i> , 2022, 06, e21-e25.	1.4	9
88	Coagulopathies in Intensive Care Medicine: Balancing Act between Thrombosis and Bleeding. <i>Journal of Clinical Medicine</i> , 2021, 10, 5369.	2.4	7
89	2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary. <i>Thrombosis and Haemostasis</i> , 2022, 122, 020-047.	3.4	192
90	High versus Standard Intensity of Thromboprophylaxis in Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 5549.	2.4	13
91	Prevention and management of thrombosis in hospitalised patients with COVID-19 pneumonia. <i>Lancet Respiratory Medicine</i> , the, 2022, 10, 214-220.	10.7	37
92	Intubation to Nowhere in COVID-19. <i>Mayo Clinic Proceedings</i> , 2022, 97, 4-6.	3.0	2
93	Treatments for COVID-19: Lessons from 2020 and new therapeutic options. <i>Current Opinion in Pharmacology</i> , 2022, 62, 43-59.	3.5	23
95	TEGÂ®, Microclot and Platelet Mapping for Guiding Early Management of Severe COVID-19 Coagulopathy. <i>Journal of Clinical Medicine</i> , 2021, 10, 5381.	2.4	30
96	Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <i>Lancet, The</i> , 2022, 399, 143-151.	13.7	199
97	Global lessons learned from COVID-19 mass casualty incidents. <i>British Journal of Anaesthesia</i> , 2022, 128, e97-e100.	3.4	7

#	ARTICLE	IF	CITATIONS
98	Cardiac inflammation and microvascular procoagulant changes are decreased in second wave compared to first wave deceased COVID-19 patients. International Journal of Cardiology, 2022, 349, 157-165.	1.7	10
99	Anticoagulant Treatment Regimens in Patients With Covid-19: A Meta-Analysis. Clinical Pharmacology and Therapeutics, 2022, 111, 614-623.	4.7	20
100	Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial. American Heart Journal, 2022, 246, 136-143.	2.7	8
101	Ocular and Systemic Complications of COVID-19: Impact on Patients and Healthcare. Clinical Ophthalmology, 2022, Volume 16, 1-13.	1.8	16
102	From the Heart to the Brain: Building Bridges to a Better Future. Stroke, 2022, , STROKEAHA121036763.	2.0	0
103	Interpreting recent clinical studies for COVID-19: A continual process with more new data. Anaesthesia, Critical Care & Pain Medicine, 2022, 41, 101016.	1.4	3
104	Use and misuse of biomarkers and the role of D-dimer and C-reactive protein in the management of COVID-19: A post-hoc analysis of a prospective cohort study. Clinics, 2021, 76, e3547.	1.5	13
105	Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. Nature Reviews Cardiology, 2022, 19, 475-495.	13.7	180
106	Efficacy and safety of therapeutic vs. prophylactic bemiparin in noncritically ill patients with COVID-19 pneumonia. European Journal of Internal Medicine, 2022, , .	2.2	3
107	Liver Injury in Patients Hospitalized for COVID-19: Possible Role of Therapy. Vaccines, 2022, 10, 192.	4.4	20
108	Clinico-histopathologic and single-nuclei RNA-sequencing insights into cardiac injury and microthrombi in critical COVID-19. JCI Insight, 2022, 7, .	5.0	14
109	Treatment of MIS-C in Children and Adolescents. Current Pediatrics Reports, 2022, 10, 1-10.	4.0	41
110	Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19. JAMA - Journal of the American Medical Association, 2022, 327, 227.	7.4	89
111	COVID-19: Les thérapeutiques. , 2022, 1, 13-13.		0
112	Serial Thromboelastography and the Development of Venous Thromboembolism in Critically Ill Patients With COVID-19. , 2022, 4, e0618.		5
113	The Central Role of Extracellular Vesicles in the Mechanisms of Thrombosis in COVID-19 Patients With Cancer and Therapeutic Strategies. Frontiers in Cell and Developmental Biology, 2021, 9, 792335.	3.7	3
114	Anticoagulation in COVID-19. Lancet, The, 2022, 399, 5-7.	13.7	18
115	Thromboelastography determined dynamics of blood coagulation and its correlation with complications and outcomes in patients with coronavirus disease 2019. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12645.	2.3	5

#	ARTICLE	IF	CITATIONS
116	A proteomic survival predictor for COVID-19 patients in intensive care. , 2022, 1, e0000007.		28
117	Intracranial Hemorrhages on Extracorporeal Membrane Oxygenation. Critical Care Medicine, 2022, Publish Ahead of Print, .	0.9	33
118	Circulating Microparticles in the Pathogenesis and Early Anticoagulation of Thrombosis in COVID-19 With Kidney Injury. Frontiers in Cell and Developmental Biology, 2021, 9, 784505.	3.7	5
119	COVID-19 and Elevated D-Dimer: A Tale of Caution. Journal of General Internal Medicine, 2022, 37, 1304-1305.	2.6	1
120	COVID-19 in the Critically Ill Pregnant Patient. Critical Care Clinics, 2022, , .	2.6	5
121	Platelets and Antiplatelet Medication in COVID-19-Related Thrombotic Complications. Frontiers in Cardiovascular Medicine, 2021, 8, 802566.	2.4	7
122	Methylprednisolone, venous thromboembolism, and association with heparin to 30Âdays in hospital survival in severe Covid-19 pneumonia. BMC Pulmonary Medicine, 2022, 22, 6.	2.0	5
123	COVID-19 and Acute Kidney Injury. Critical Care Clinics, 2022, 38, 473-489.	2.6	21
124	Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Lancet, The, 2022, 399, 50-59.	13.7	172
125	Fibrinolytics as an ARDS Salvage Option. Chest, 2022, 161, 595-596.	0.8	0
126	Anticoagulation Prior to COVID-19 Infection Has No Impact on 6 Months Mortality: A Propensity Scoreâ€”Matched Cohort Study. Journal of Clinical Medicine, 2022, 11, 352.	2.4	10
127	Antiplatelet Therapy in Patients With COVID-19â€”More Is Less?. JAMA - Journal of the American Medical Association, 2022, 327, 223.	7.4	10
128	Arrhythmias in the COVID-19 patient. Heart Rhythm O2, 2022, 3, 8-14.	1.7	12
129	A guide to immunotherapy for COVID-19. Nature Medicine, 2022, 28, 39-50.	30.7	206
131	Effects of dalteparin on antiâ€”Xa activities cannot be predicted in critically ill COVIDâ€”19 patients. British Journal of Clinical Pharmacology, 2021, , .	2.4	4
132	Thromboprophylaxis for COVID-19-related coagulopathy: what next?. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, , .	3.0	1
133	Updated meta-analysis of randomized controlled trials on the safety and efficacy of different prophylactic anticoagulation dosing regimens in non-critically ill hospitalized patients with COVID-19. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, E15-E17.	3.0	15
134	Resilient Clinical Trial Infrastructure in Response to the COVID-19 Pandemic: Lessons Learned from the TOGETHER Randomized Platform Clinical Trial. American Journal of Tropical Medicine and Hygiene, 2022, 106, 389-393.	1.4	1

#	ARTICLE	IF	CITATIONS
135	Non-severe COVID-19 is associated with endothelial damage and hypercoagulability despite pharmacological thromboprophylaxis. Journal of Thrombosis and Haemostasis, 2022, 20, 1008-1014.	3.8	18
136	Thrombosis and fibrosis: mutually inclusive targets to combat in COVID-19. Future Science OA, 2022, 8, FSO777.	1.9	1
137	Dexamethasone Improves Cardiovascular Outcomes in Critically Ill COVID-19, a Real World Scenario Multicenter Analysis. Frontiers in Medicine, 2022, 9, 808221.	2.6	6
138	Thromboembolic complications during and after hospitalization for COVID-19: Incidence, risk factors and thromboprophylaxis. Thrombosis Update, 2022, 6, 100096.	0.9	2
139	Pattern of medication utilization in hospitalized patients with COVID-19 in three District Headquarters Hospitals in the Punjab province of Pakistan. Exploratory Research in Clinical and Social Pharmacy, 2022, 5, 100101.	1.0	8
140	Anticoagulation as a therapeutic strategy for hospitalised patients with COVID-19. Thrombosis Update, 2022, 6, 100097.	0.9	1
141	Multi-organ point-of-care ultrasound for detection of pulmonary embolism in critically ill COVID-19 patients – A diagnostic accuracy study. Journal of Critical Care, 2022, 69, 153992.	2.2	5
142	Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. European Heart Journal, 2022, 43, 1157-1172.	2.2	297
143	Rectus Sheath Hematoma in COVID-19 Patients as a Mortal Complication: A Retrospective Report. International Journal of Clinical Practice, 2022, 2022, 1-7.	1.7	8
144	COVID-19 Coagulopathy: From Pathogenesis to Treatment. Acta Haematologica, 2022, 145, 282-296.	1.4	19
146	Viscoelastic Hemostatic Assays: A Primer on Legacy and New Generation Devices. Journal of Clinical Medicine, 2022, 11, 860.	2.4	41
147	Thrombosis pathways in COVID-19 versus influenza-associated ARDS: a targeted proteomics approach. Journal of Thrombosis and Haemostasis, 2022, , .	3.8	4
148	Comparison between standard Vs. Escalated dose venous thromboembolism (VTE) prophylaxis in critically ill patients with COVID-19: A two centers, observational study. Saudi Pharmaceutical Journal, 2022, 30, 398-406.	2.7	5
149	Thromboprophylaxis in Patients With COVID-19. Chest, 2022, 162, 213-225.	0.8	58
150	Community-Acquired Pneumonia in Canada During Coronavirus Disease 2019. Open Forum Infectious Diseases, 2022, 9, ofac043.	0.9	4
151	Regional citrate and systemic heparin are adequate to maintain filter half-life for COVID-19 patients on continuous renal replacement therapy. Seminars in Dialysis, 2022, , .	1.3	2
152	American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 3. Arthritis and Rheumatology, 2022, 74, .	5.6	146
153	Use of Systemic Anticoagulation in COVID-19: Delving Beyond Theoretical Hypothesis. Cureus, 2022, 14, e22061.	0.5	0

#	ARTICLE	IF	CITATIONS
154	The association between anticoagulation and adverse outcomes after a positive SARS-CoV-2 test among older outpatients: A population-based cohort study. <i>Thrombosis Research</i> , 2022, 211, 114-122.	1.7	5
155	Therapeutic Options for Coronavirus Disease 2019 (COVID-19): Where Are We Now?. <i>Current Infectious Disease Reports</i> , 2021, 23, 28.	3.0	5
156	Real-Life Effectiveness and Safety of Baricitinib as Adjunctive to Standard-of-Care Treatment in Hospitalized Patients With Severe Coronavirus Disease 2019. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab588.	0.9	7
157	Alveolar, Endothelial, and Organ Injury Marker Dynamics in Severe COVID-19. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 507-519.	5.6	56
158	The impact of therapeutics on mortality in hospitalised patients with COVID-19: systematic review and meta-analyses informing the European Respiratory Society living guideline. <i>European Respiratory Review</i> , 2021, 30, 210171.	7.1	20
159	Heparin and SARS-CoV-2: Multiple Pathophysiological Links. <i>Viruses</i> , 2021, 13, 2486.	3.3	10
160	Heparin-induced thrombocytopenia in COVID-19: A systematic review. <i>Anesthesia: Essays and Researches</i> , 2021, 15, 341.	0.5	4
161	Active site prediction of phosphorylated SARS-CoV-2 N-Protein using molecular simulation. <i>Informatics in Medicine Unlocked</i> , 2022, 29, 100889.	3.4	1
162	Anticoagulants and corticosteroids in COVID-19: What do we know so far?. <i>Srpski Medicinski Åasopis Lekarske Komore</i> , 2022, 3, 62-74.	0.1	1
163	Report of Low Incidence of Thrombosis with Early Prophylaxis in Hospitalized Patients with COVID-19 from Two Saudi Tertiary Centers. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962210862.	1.7	2
164	â€œMATH+â€•Multi-Modal Hospital Treatment Protocol for COVID-19 Infection: Clinical and Scientific Rationale. <i>Journal of Clinical Medicine Research</i> , 2022, 14, 53-79.	1.2	4
165	A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications. <i>Biochemical Journal</i> , 2022, 479, 537-559.	3.7	126
166	Contribution of the elevated thrombosis risk of males to the excess male mortality observed in COVID-19: an observational study. <i>BMJ Open</i> , 2022, 12, e051624.	1.9	4
167	Multicenter STudy of tissue plasminogen activator (alteplase) use in COVIDâ€™19 severe respiratory failure (MUST COVID): Aâ€™retrospective cohort study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12669.	2.3	6
168	COVID-19 in dialysis: clinical impact, immune response, prevention, and treatment. <i>Kidney International</i> , 2022, 101, 883-894.	5.2	82
171	COVIDâ€™19 and venous thromboembolism: A narrative review. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12666.	2.3	16
172	COVID-19 ARDS: One Pathogen, Multiple Phenotypes. <i>Critical Care Clinics</i> , 2022, , .	2.6	6
173	European Society of Cardiology Highlights: Late-breaking Trials â€™ COVID-19. <i>European Cardiology Review</i> , 2022, 17, e04.	2.2	0

#	ARTICLE	IF	CITATIONS
174	Treatment Outcomes of Tocilizumab in Critically-Ill COVID-19 Patients, Single-Centre Retrospective Study. <i>Antibiotics</i> , 2022, 11, 241.	3.7	4
175	Left Ventricular Thrombus of Unknown Etiology in a Patient With COVID-19 Disease With No Significant Medical History. <i>Cardiovascular Revascularization Medicine</i> , 2022, 40, 329-331.	0.8	2
176	Anticoagulation Strategies in Critically Ill Patients With SARS-CoV-2 Infection: The Role of Direct Thrombin Inhibitors. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2022, 36, 2961-2967.	1.3	4
177	The Anti-Coronavirus Therapies (ACT) Trials: Design, Baseline Characteristics, and Challenges. <i>CJC Open</i> , 2022, 4, 568-576.	1.5	4
178	The COVID Complex: A Review of Platelet Activation and Immune Complexes in COVID-19. <i>Frontiers in Immunology</i> , 2022, 13, 807934.	4.8	24
179	Risk Factors of Venous Thromboembolism in Noncritically Ill Patients Hospitalized for Acute COVID-19 Pneumonia Receiving Prophylactic-Dose Anticoagulation. <i>Viruses</i> , 2022, 14, 737.	3.3	7
180	Low versus high dose anticoagulation in patients with Coronavirus 2019 pneumonia at the time of admission to critical care units: A multicenter retrospective cohort study in the Beaumont healthcare system. <i>PLoS ONE</i> , 2022, 17, e0265966.	2.5	2
181	How far are we from predicting multi-drug interactions during treatment for COVID-19 infection?. <i>British Journal of Pharmacology</i> , 2022, 179, 3831-3838.	5.4	1
182	Full <i>versus</i> prophylactic-intermediate doses of anticoagulants in COVID-19: a meta-analysis. <i>Haematologica</i> , 2022, 107, 1933-1939.	3.5	5
183	COUNTERPOINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? No. <i>Chest</i> , 2022, 161, 1448-1451.	0.8	6
185	Impact of Thromboprophylaxis Intensity on Patients' Mortality Among Hospitalized Patients with COVID-19: A Propensity-Score Matched Study. <i>Clinical Epidemiology</i> , 2022, Volume 14, 361-368.	3.0	1
186	Clinical Evidence Generation During a Pandemic. <i>Cancer Journal (Sudbury, Mass)</i> , 2022, 28, 151-156.	2.0	2
187	Cardiovascular Dysfunction in COVID-19: Association Between Endothelial Cell Injury and Lactate. <i>Frontiers in Immunology</i> , 2022, 13, 868679.	4.8	7
188	Cardiovascular drugs and COVID-19 clinical outcomes: a systematic review and meta-analysis of randomized controlled trials. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3577-3599.	2.4	7
189	Successful treatment of intracardiac thrombosis in the presence of fulminant myocarditis requiring ECMO associated with COVID-19. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 849-851.	0.6	1
191	Immunothrombosis and the molecular control of tissue factor by pyroptosis: prospects for new anticoagulants. <i>Biochemical Journal</i> , 2022, 479, 731-750.	3.7	9
192	What Are Adaptive Platform Clinical Trials and What Role May They Have in Cardiovascular Medicine?. <i>Circulation</i> , 2022, 145, 629-632.	1.6	19
193	Thrombosis and coagulopathy in COVID-19 patients receiving ECMO: a narrative review of current literature. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2022, 36, 3312-3317.	1.3	6

#	ARTICLE	IF	CITATIONS
194	Coagulation factor V is a T-cell inhibitor expressed by leukocytes in COVID-19. IScience, 2022, 25, 103971.	4.1	7
195	Anticoagulation in Patients With COVID-19. Journal of the American College of Cardiology, 2022, 79, 917-928.	2.8	35
196	Coagulopathy and Fibrinolytic Pathophysiology in COVID-19 and SARS-CoV-2 Vaccination. International Journal of Molecular Sciences, 2022, 23, 3338.	4.1	11
197	One Year Prevalence of Venous Thromboembolism in Hospitalized COVID-19 Patients in France: Patients' Characteristics, Time Trends, and Outcomes. Thrombosis and Haemostasis, 2022, 122, 1532-1541.	3.4	5
198	Whole-genome sequencing reveals host factors underlying critical COVID-19. Nature, 2022, 607, 97-103.	27.8	174
199	POINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? Yes. Chest, 2022, 161, 1446-1448.	0.8	8
200	The Future of Critical Care: Optimizing Technologies and a Learning Healthcare System to Potentiate a More Humanistic Approach to Critical Care. , 2022, 4, e0659.		11
201	Coreceptor functions of cell surface heparan sulfate proteoglycans. American Journal of Physiology - Cell Physiology, 2022, 322, C896-C912.	4.6	20
202	Effect of plasma exchange on COVID-19 associated excess of von Willebrand factor and inflammation in critically ill patients. Scientific Reports, 2022, 12, 4801.	3.3	10
203	Prophylactic anticoagulation with low molecular weight heparin in COVID-19: cohort studies in Denmark and Sweden. Clinical Microbiology and Infection, 2022, 28, 1291.e1-1291.e5.	6.0	3
205	In Situ Pulmonary Thrombolysis and Perfusion Lung Angiography in Severe COVID-19 Respiratory Failure. , 2022, 4, e0670.		0
206	Efficacy of different anticoagulant doses for patients with COVID-19: a systematic review and network meta-analysis. Infection, 2022, 50, 1453-1463.	4.7	4
207	Rebuttal From Dr David Jimenez et Al. Chest, 2022, 161, 1453-1455.	0.8	0
208	Role of Acute Thrombosis in COVID-19. Critical Care Clinics, 2022, , .	2.6	3
210	Tools to Reduce Low-Value Care: Lessons From COVID-19 Pandemic; Comment on "Key Factors That Promote Low-Value Care: Views of Experts From the United States, Canada, and the Netherlands". International Journal of Health Policy and Management, 2022, , .	0.9	0
211	Intestinal Damage in COVID-19: SARS-CoV-2 Infection and Intestinal Thrombosis. Frontiers in Microbiology, 2022, 13, 860931.	3.5	15
212	Shining a light on platelet activation in COVID-19. Journal of Thrombosis and Haemostasis, 2022, , .	3.8	3
213	Naloxegol to Prevent Constipation in ICU Adults Receiving Opioids: A Randomized Double-Blind Placebo-Controlled Pilot Trial. Critical Care Research and Practice, 2022, 2022, 1-10.	1.1	1

#	ARTICLE	IF	CITATIONS
214	Factores de riesgo de mortalidad en pacientes con infección por SARS-CoV-2 y fibrilación auricular: datos del registro SEMI-COVID-19. Medicina Clínica, 2022, 159, 457-464.	0.6	4
215	Extracardiac Prothrombotic Effects of COVID-19. Cardiology Clinics, 2022, , .	2.2	2
216	D-Dimer Values and Venous Thromboembolism in Patients With COVID-19 in Japan – From the CLOT-COVID Study –. Circulation Reports, 2022, , .	1.0	4
218	Thromboprophylaxis in COVID-19: Weight and severity adjusted intensified dosing. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12683.	2.3	4
219	Challenging management dogma where evidence is non-existent, weak or outdated. Intensive Care Medicine, 2022, 48, 548-558.	8.2	10
220	D-dimer and CoV-2 spike-immune complexes contribute to the production of PGE2 and proinflammatory cytokines in monocytes. PLoS Pathogens, 2022, 18, e1010468.	4.7	7
221	COVID-19 therapeutics: Challenges and directions for the future. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2119893119.	7.1	92
222	Thromboinflammation and Antithrombotics in COVID-19. JAMA - Journal of the American Medical Association, 2022, 327, 1234.	7.4	9
223	Persistent Lung Injury and Prothrombotic State in Long COVID. Frontiers in Immunology, 2022, 13, 862522.	4.8	15
224	Association between pre-admission anticoagulation and in-hospital death, venous thromboembolism, and major bleeding among hospitalized COVID-19 patients in Japan. Pharmacoepidemiology and Drug Safety, 2022, 31, 680-688.	1.9	5
225	Intensive-Dose Tinzaparin in Hospitalized COVID-19 Patients: The INTERACT Study. Viruses, 2022, 14, 767.	3.3	4
226	The current status of thrombosis and anticoagulation therapy in patients with COVID-19 in Japan: From the CLOT-COVID study. Journal of Cardiology, 2022, 80, 285-291.	1.9	18
227	Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19. JAMA - Journal of the American Medical Association, 2022, 327, 1247.	7.4	83
228	Efficacy of the combination of baricitinib, remdesivir, and dexamethasone in hypoxic adults with COVID-19: A retrospective study. Respiratory Medicine and Research, 2022, 81, 100903.	0.6	3
229	Influence of sex on development of thrombosis in patients with COVID-19: From the CLOT-COVID study. Thrombosis Research, 2022, 213, 173-178.	1.7	12
230	Clinical update on COVID-19 for the emergency and critical care clinician: Medical management. American Journal of Emergency Medicine, 2022, 56, 158-170.	1.6	13
231	(Acute pulmonary embolism). Cor Et Vasa, 2021, 63, 675-682.	0.1	0
233	Pre- and in-hospital anticoagulation therapy in coronavirus disease 2019 patients: a propensity-matched analysis of in-hospital outcomes. Journal of Cardiovascular Medicine, 2022, 23, 264-271.	1.5	12

#	ARTICLE	IF	CITATIONS
235	Nebulized enriched heparin to treat no critical patients with Sars-Cov-2. Medicine (United States), 2021, 100, e28288.	1.0	3
236	Comparison of Higher-Than-Standard to D-Dimer Driven Thromboprophylaxis in Hospitalized Patients With COVID-19. Hospital Pharmacy, 0, , 001857872110664.	1.0	1
237	The Pathobiological Basis for Thrombotic Complications in COVID-19: a Review of the Literature. Current Pathobiology Reports, 2021, 9, 107-117.	3.4	6
238	Randomized trials of therapeutic heparin for COVID-19: A meta-analysis. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12638.	2.3	39
239	Immunomonitoring of Monocyte and Neutrophil Function in Critically Ill Patients: From Sepsis and/or Trauma to COVID-19. Journal of Clinical Medicine, 2021, 10, 5815.	2.4	6
240	Risk Factors for Venous Thromboembolism in Severe COVID-19: A Study-Level Meta-Analysis of 21 Studies. International Journal of Environmental Research and Public Health, 2021, 18, 12944.	2.6	19
241	COVID-19 and thrombosis: searching for evidence. Hematology American Society of Hematology Education Program, 2021, 2021, 621-627.	2.5	12
242	Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: The X-COVID-19 Randomized Trial. European Journal of Clinical Investigation, 2022, 52, e13735.	3.4	31
243	Thrombotic and Clinical Outcomes in Patients with Hematologic Malignancy and COVID-19. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.4	2
244	MPN and thrombosis was hard enough .Â. now there's COVID-19 thrombosis too. Hematology American Society of Hematology Education Program, 2021, 2021, 710-717.	2.5	2
245	Clinical features and acute management of COVID-19 in adults. , 2021, , 101-123.		2
246	The European clinical research response to optimise treatment of patients with COVID-19: lessons learned, future perspective, and recommendations. Lancet Infectious Diseases, The, 2022, 22, e153-e158.	9.1	22
248	Safety and Efficacy of Intermediate- and Therapeutic-Dose Anticoagulation for Hospitalised Patients with COVID-19: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2022, 11, 57.	2.4	11
249	COVID-19 and immunothrombosis: Pathophysiology and therapeutic implications. Critical Reviews in Oncology/Hematology, 2021, 168, 103529.	4.4	22
250	Lessening Organ Dysfunction With Vitamin C (LOVIT) Trial: Statistical Analysis Plan. JMIR Research Protocols, 2022, 11, e36261.	1.0	3
251	First do no harm. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12694.	2.3	2
252	Anticoagulation as secondary prevention of massive lung thromboses in hospitalized patients with COVID-19. European Journal of Internal Medicine, 2022, 100, 21-24.	2.2	7
253	Heparanase Blockade as a Novel Dual-Targeting Therapy for COVID-19. Journal of Virology, 2022, 96, e0005722.	3.4	14

#	ARTICLE	IF	CITATIONS
254	Preinfection Anticoagulation/Antiplatelet Therapy Does Not Influence the Outcome of COVID-19 Disease in Hospitalized Patients. American Journal of Therapeutics, 2022, Publish Ahead of Print, .	0.9	0
255	New Insights in the Occurrence of Venous Thromboembolism in Critically Ill Patients with COVID-19—A Large Postmortem and Clinical Analysis. Viruses, 2022, 14, 811.	3.3	3
256	COVID-19 and Cardiac Arrhythmias: a Contemporary Review. Current Treatment Options in Cardiovascular Medicine, 2022, 24, 87-107.	0.9	15
257	COVID-19 Vasculitis and vasculopathy-Distinct immunopathology emerging from the close juxtaposition of Type II Pneumocytes and Pulmonary Endothelial Cells. Seminars in Immunopathology, 2022, 44, 375-390.	6.1	15
258	Acute Arterial Occlusions in COVID-19 Times: A Comparison Study Among Patients with Acute Limb Ischemia With or Without COVID-19 Infection. Annals of Vascular Surgery, 2022, 83, 80-86.	0.9	3
259	Physiology Is Vital to Precision Medicine in Acute Respiratory Distress Syndrome and Sepsis. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 14-16.	5.6	10
260	Management of patients with SARS-CoV-2 infections with focus on patients with chronic lung diseases (as of 10 January 2022). Wiener Klinische Wochenschrift, 2022, 134, 399-419.	1.9	1
261	To Anticoagulate or Not to Anticoagulate in COVID-19: Lessons after 2 Years. Seminars in Thrombosis and Hemostasis, 2023, 49, 062-072.	2.7	13
262	Automated measurement of coagulation and fibrinolytic activation markers: Outcomes in coronavirus disease 2019 (<scp>COVID</scp>â€19) patients. International Journal of Laboratory Hematology, 2022, 44, 817-822.	1.3	3
263	Epidemiology and Management of STâ€Segmentâ€Elevation Myocardial Infarction in Patients With COVIDâ€19: A Report From the American Heart Association COVIDâ€19 Cardiovascular Disease Registry. Journal of the American Heart Association, 2022, 11, e024451.	3.7	6
264	Evaluation of Low-Dose Aspirin use among Critically Ill Patients with COVID-19: A Multicenter Propensity Score Matched Study. Journal of Intensive Care Medicine, 2022, 37, 1238-1249.	2.8	3
265	Clinical features of thrombosis and bleeding in COVID-19. Blood, 2022, 140, 184-195.	1.4	29
267	Thromboembolic Events in Deceased Patients with Proven SARS-CoV-2 Infection: Frequency, Characteristics and Risk Factors. SSRN Electronic Journal, 0, , .	0.4	0
268	The Association between the Development of Thrombosis and Worsening of Disease Severity in Patients with Moderate COVID-19 on Admission: From the CLOT-COVID Study. SSRN Electronic Journal, 0, , .	0.4	1
269	Ischemic Stroke and SARS-CoV-2 Infection: The Bidirectional Pathology and Risk Morbidities. Neurology International, 2022, 14, 391-405.	2.8	25
270	Oxygen-Free Days as an Outcome Measure in Clinical Trials of Therapies for COVID-19 and Other Causes of New-Onset Hypoxemia. Chest, 2022, 162, 804-814.	0.8	10
271	Stroke Treatment in the Era of COVID-19: a Review. Current Treatment Options in Neurology, 2022, 24, 155-171.	1.8	9
272	Use of Anticoagulants in COVID-19: A Review. American Journal of Therapeutics, 2022, 29, e425-e436.	0.9	4

#	ARTICLE	IF	CITATIONS
273	A Home-Treatment Algorithm Based on Anti-inflammatory Drugs to Prevent Hospitalization of Patients With Early COVID-19: A Matched-Cohort Study (COVER 2). <i>Frontiers in Medicine</i> , 2022, 9, 785785.	2.6	15
274	COVID-19 in Patients with Pulmonary Hypertension: A National Prospective Cohort Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 573-583.	5.6	16
277	Reflections on defining a standard for computable expression of scientific knowledge: What teach us Yoda can. <i>Learning Health Systems</i> , 0, , .	2.0	0
278	A case of severe COVID-19 with pulmonary thromboembolism related to heparin-induced thrombocytopenia during prophylactic anticoagulation therapy. <i>Journal of Infection and Chemotherapy</i> , 2022, , .	1.7	3
280	Venous thromboembolism in COVID-19 patients and prediction model: a multicenter cohort study. <i>BMC Infectious Diseases</i> , 2022, 22, 462.	2.9	17
281	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients. <i>Blood Advances</i> , 2022, 6, 4915-4923.	5.2	42
282	Double Trouble: A Case of Two Simultaneous Thrombotic Events in a Patient With COVID-19. <i>Cureus</i> , 2022, , .	0.5	0
283	Obesity and Its Impact on Adverse In-Hospital Outcomes in Hospitalized Patients With COVID-19. <i>Frontiers in Endocrinology</i> , 2022, 13, 876028.	3.5	11
285	Venous thromboembolism (VTE) prevention and diagnosis in COVID-19: Practice patterns and outcomes at 33 hospitals. <i>PLoS ONE</i> , 2022, 17, e0266944.	2.5	4
286	Anticoagulant Treatment in Severe ARDS COVID-19 Patients. <i>Journal of Clinical Medicine</i> , 2022, 11, 2695.	2.4	4
287	Immuno-Thrombotic Complications of COVID-19: Implications for Timing of Surgery and Anticoagulation. <i>Frontiers in Surgery</i> , 2022, 9, .	1.4	23
288	Assessment of Bleeding Risk in Hospitalized COVID-19 Patients: A Tertiary Hospital Experience during the Pandemic in a Predominant Minority Populationâ€”Bleeding Risk Factors in COVID-19 Patients. <i>Journal of Clinical Medicine</i> , 2022, 11, 2754.	2.4	2
289	Plasma Proteomics of COVID-19â€™Associated Cardiovascular Complications. <i>JACC Basic To Translational Science</i> , 2022, 7, 425-441.	4.1	17
290	COVID-19 associated rhabdomyolysis leading to major amputation in the absence of macrovascular thrombosis. <i>Annals of Vascular Surgery Brief Reports and Innovations</i> , 2022, 2, 100082.	0.2	2
292	Venous and arterial thrombosis in COVID-19: An updated narrative review. <i>Journal of Infection and Public Health</i> , 2022, 15, 689-702.	4.1	6
293	Comparison of standard prophylactic, intermediate prophylactic and therapeutic anticoagulation in patients with severe COVID-19: protocol for the ANTICOVID multicentre, parallel-group, open-label, randomised controlled trial. <i>BMJ Open</i> , 2022, 12, e059383.	1.9	3
294	Evaluating Primary Endpoints for COVID-19 Therapeutic Trials to Assess Recovery. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 730-739.	5.6	10
295	Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 54, 197-210.	2.1	29

#	ARTICLE	IF	CITATIONS
296	Diagnosis and management of covid-19 in pregnancy. BMJ, The, 2022, 377, e069739.	6.0	25
297	Double Jeopardy: Precapillary Pulmonary Hypertension Increases the Risk of Hospitalization and Death from COVID-19. American Journal of Respiratory and Critical Care Medicine, 2022, , .	5.6	0
298	Screening the Potential Biomarkers of COVID-19-Related Thrombosis Through Bioinformatics Analysis. Frontiers in Genetics, 2022, 13, .	2.3	0
299	Therapeutic anticoagulation to prevent thrombosis, coagulopathy, and mortality in severe COVID-19: The Swiss COVID-19 HEP randomized clinical trial. Research and Practice in Thrombosis and Haemostasis, 2022, 6, .	2.3	18
300	COVID-19 associated coagulopathy and thrombosis in cancer. Thrombosis Research, 2022, 213, S72-S76.	1.7	1
301	Venous Gangrene Associated with COVID-19: Successful Limb Preservation Strategies with Optimal Wound Management. Annals of Vascular Surgery Brief Reports and Innovations, 2022, , 100095.	0.2	0
302	Prophylactic Anticoagulation and Thrombosis in Hospitalized Patients with Clinically Stable COVID-19 at Admission: From the CLOT-COVID Study. SSRN Electronic Journal, 0, , .	0.4	0
303	Thromboprophylaxis and anticoagulation for inpatients with coronavirus disease 2019 in 2022 and beyond. Clinical Microbiology and Infection, 2022, , .	6.0	0
304	D-dimer testing in clinical practice in the era of COVID-19. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12730.	2.3	9
305	Acute Coronary Syndrome in the COVID-19 Era—Differences and Dilemmas Compared to the Pre-COVID-19 Era. Journal of Clinical Medicine, 2022, 11, 3024.	2.4	11
306	The Role of Heparin in COVID-19: An Update after Two Years of Pandemics. Journal of Clinical Medicine, 2022, 11, 3099.	2.4	13
307	Therapeutic Trends of Cerebrovascular Disease during the COVID-19 Pandemic and Future Perspectives. Journal of Stroke, 2022, 24, 179-188.	3.2	12
308	To escalate thromboprophylactic heparin intensity in COVID-19 or not? That is still the question. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12738.	2.3	2
309	Safety and Efficacy Analysis of Apixaban Compared to Heparins in Hospitalized Non-Critically Ill COVID-19 Patients. Hospital Pharmacy, 2022, 57, 727-733.	1.0	3
310	Antithrombotic agents in patients with COVID-19. Cmaj, 2022, 194, E704-E704.	2.0	1
311	SARS-CoV-2 RNA copy number is a factor associated with the mortality of COVID-19 and improves the predictive performance of mortality in severe cases.. Japanese Journal of Infectious Diseases, 2022, , .	1.2	0
312	Anticoagulation in hospitalized patients with COVID-19. Blood, 2022, 140, 809-814.	1.4	12
313	Thrombotic events in critically ill children with coronavirus disease 2019 or multisystem inflammatory syndrome in children. Current Opinion in Pediatrics, 2022, 34, 261-267.	2.0	4

#	ARTICLE	IF	CITATIONS
314	A systems biology approach identifies candidate drugs to reduce mortality in severely ill patients with COVID-19. Science Advances, 2022, 8, .	10.3	14
315	Therapeutic anticoagulation using heparin in early phase severe coronavirus disease 2019: A retrospective study. American Journal of Emergency Medicine, 2022, 58, 84-88.	1.6	0
316	Statins and Risk of Thrombosis in Critically ill Patients with COVID-19: A Multicenter Cohort Study. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962211038.	1.7	4
317	Heparin-Induced Thrombocytopenia in COVID-19. , 2022, 19, .		0
318	Management of Acute Respiratory Distress Syndrome in COVID-19 Patients. Acta Anaesthesiologica Belgica, 2022, 73, 5-14.	0.1	0
319	An adaptive platform trial for evaluating treatments in patients with life-threatening hemorrhage from traumatic injuries: Rationale and proposal. Transfusion, 2022, 62, .	1.6	2
320	Use of pragmatic and explanatory trial designs in acute care research: lessons from COVID-19. Lancet Respiratory Medicine,the, 2022, 10, 700-714.	10.7	22
321	New Insights into Clinical and Mechanistic Heterogeneity of the Acute Respiratory Distress Syndrome: Summary of the Aspen Lung Conference 2021. American Journal of Respiratory Cell and Molecular Biology, 2022, 67, 284-308.	2.9	9
322	COVID-19 and Thrombosis: Pathophysiological Mechanisms and Therapeutic Update. , 0, , .		1
323	Role of anticoagulation in lowering the mortality in hospitalized covid-19 patients. Journal of King Abdulaziz University, Islamic Economics, 2022, 43, 541-550.	1.1	0
324	Annals for Hospitalists Inpatient Notes - Venous Thromboembolism Prophylaxis in COVID-19: Making Sense of the Evidence. Annals of Internal Medicine, 2022, 175, HO2-HO3.	3.9	1
325	An adaptive platform trial for evaluating treatments in patients with life-threatening hemorrhage from traumatic injuries: Ethical and <scp>US</scp> regulatory considerations. Transfusion, 2022, 62, .	1.6	2
326	An adaptive platform trial for evaluating treatments in patients with life-threatening hemorrhage from traumatic injuries: Planning and execution. Transfusion, 2022, 62, .	1.6	2
327	Special Issue on "Disseminated Intravascular Coagulation: Current Understanding and Future Perspectives". Journal of Clinical Medicine, 2022, 11, 3315.	2.4	0
328	Effect of intermediate/high versus low dose heparin on the thromboembolic and hemorrhagic risk of unvaccinated COVID-19 patients in the emergency department. BMC Emergency Medicine, 2022, 22, .	1.9	0
329	2022 AHA/ACC Key Data Elements and Definitions for Cardiovascular and Noncardiovascular Complications of COVID-19. Journal of the American College of Cardiology, 2022, , .	2.8	7
330	Effect of heparin treatment on pulmonary embolism and in-hospital death in unvaccinated COVID-19 patients without overt deep vein thrombosis. Thrombosis Journal, 2022, 20, .	2.1	1
331	Full Characterization of Thrombotic Events in All Hospitalized COVID-19 Patients in a Spanish Tertiary Hospital during the First 18 Months of the Pandemic. Journal of Clinical Medicine, 2022, 11, 3443.	2.4	5

#	ARTICLE	IF	CITATIONS
332	COVID-19 coagulopathy – what should we treat?. <i>Experimental Physiology</i> , 2022, 107, 749-758.	2.0	8
333	Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2022, 10, 1128-1136.	1.6	4
334	2022 AHA/ACC Key Data Elements and Definitions for Cardiovascular and Noncardiovascular Complications of COVID-19: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 0, .	2.2	5
335	Aspirin Therapy on Prophylactic Anticoagulation for Patients Hospitalized With COVID-19: A Propensity Score-Matched Cohort Analysis of the HOPE-19 Registry. <i>Journal of the American Heart Association</i> , 2022, 11, .	3.7	8
336	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients. <i>Blood Advances</i> , 2022, 6, 4975-4982.	5.2	21
337	Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. <i>European Respiratory Journal</i> , 2022, 60, 2200803.	6.7	22
338	Efficacy and Safety of Intensified Versus Standard Prophylactic Anticoagulation Therapy in Patients With Coronavirus Disease 2019: A Systematic Review and Meta-Analysis. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	4
339	Pharmacological Studies in Hospitalized COVID-19 Patients in Belgium: We Could Do Better. <i>Viruses</i> , 2022, 14, 1427.	3.3	1
340	Thromboelastometry Predicts Thromboembolic Events, Hospital Length of Stay, and Mortality in Patients with COVID-19 Infection and Mild Hypoxemia: A Prospective Observational Study. <i>Journal of Blood Medicine</i> , 0, Volume 13, 363-372.	1.7	1
341	Clinical applications of machine learning in the survival prediction and classification of sepsis: coagulation and heparin usage matter. <i>Journal of Translational Medicine</i> , 2022, 20, .	4.4	9
342	Management of Cardiovascular Disease in Patients With COVID-19 and Chronic Chagas Disease: Implications to Prevent a Scourge Still Larger. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	1
343	Differences in clinical features and mortality in very old unvaccinated patients (≥ 80 years) hospitalized with COVID-19 during the first and successive waves from the multicenter SEMI-COVID-19 Registry (Spain). <i>BMC Geriatrics</i> , 2022, 22, .	2.7	6
344	High-dose versus low-dose venous thromboprophylaxis in hospitalized patients with COVID-19: a systematic review and meta-analysis. <i>Internal and Emergency Medicine</i> , 2022, 17, 1817-1825.	2.0	8
345	Emerging clinical trial designs may accelerate translation in hematology: lessons from COVID-19. <i>Blood Advances</i> , 2022, 6, 4710-4714.	5.2	5
346	Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial. <i>Lancet Haematology</i> , 2022, 9, e594-e604.	4.6	38
347	The Impact of Key Secular Trends During the first Three Waves the COVID-19 Pandemic. <i>Annals of Epidemiology</i> , 2022, .	1.9	2
348	Upcoming and urgent challenges in critical care research based on COVID-19 pandemic experience. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2022, , 101121.	1.4	2
349	Efficacy and safety of hyperbaric oxygen treatment to treat COVID-19 pneumonia: a living systematic review update. <i>Diving and Hyperbaric Medicine</i> , 2022, 52, 126-135.	0.5	2

#	ARTICLE	IF	CITATIONS
350	Current Effective Therapeutics in Management of COVID-19. Journal of Clinical Medicine, 2022, 11, 3838.	2.4	23
351	The effect of low-dose and high-dose low-molecular-weight-heparin and aspirin thromboprophylaxis on clinical outcome and mortality in critical ill patients with COVID-19. Journal of King Abdulaziz University, Islamic Economics, 2022, 43, 715-722.	1.1	1
352	COVID-19 increases the risk for the onset of atrial fibrillation in hospitalized patients. Scientific Reports, 2022, 12, .	3.3	25
354	ISTH guidelines for antithrombotic treatment in COVID-19. Journal of Thrombosis and Haemostasis, 2022, 20, 2214-2225.	3.8	100
355	Thromboprophylaxis in people hospitalized with COVID-19: Assessing intermediate or standard doses in a retrospective cohort study. Research and Practice in Thrombosis and Haemostasis, 2022, 6, .	2.3	0
356	Clinical Characteristics and Treatment Outcomes of COVID-19 Patients at Eka Kotebe General Hospital, Addis Ababa, Ethiopia. American Journal of Tropical Medicine and Hygiene, 2022, 107, 252-259.	1.4	1
357	Dynamics of disease characteristics and clinical management of critically ill COVID-19 patients over the time course of the pandemic: an analysis of the prospective, international, multicentre RISC-19-ICU registry. Critical Care, 2022, 26, .	5.8	11
358	Thromboprophylaxis Strategies for Hospitalized Patients With COVID-19. Chest, 2022, 162, e69-e70.	0.8	1
359	Association Between the Development of Thrombosis and Worsening of Disease Severity in Patients With Moderate COVID-19 on Admission From the CLOT-COVID Study. Circulation Journal, 2023, 87, 448-455.	1.6	3
360	Venous Thromboembolism in Sepsis: From Bench to Bedside. Biomedicines, 2022, 10, 1651.	3.2	5
361	Coronavirus Disease 2019-Related Extensive Thrombosis in a Patient Receiving Therapeutic Anticoagulation With Dabigatran. Hospital Pharmacy, 0, , 001857872211087.	1.0	1
362	Antiphospholipid antibodies and vitamin D deficiency in COVID-19 infection with and without venous or arterial thrombosis: A pilot case-control study. PLoS ONE, 2022, 17, e0269466.	2.5	3
363	Heparin Resistance in SARS-CoV-2 Infected Patients with Venous Thromboembolism. Hospital Pharmacy, 0, , 001857872211117.	1.0	1
364	Bleeding and thrombotic events in patients with severe COVID-19 supported with extracorporeal membrane oxygenation: a nationwide cohort study. Intensive Care Medicine, 2022, 48, 1039-1052.	8.2	33
365	Heart failure in general and cardiac transplant patients with COVID-19. World Journal of Cardiology, 2022, 14, 392-402.	1.5	0
366	Thromboembolic Disease in Patients With Cancer and COVID-19: Risk Factors, Prevention and Practical Thromboprophylaxis Recommendations—State-of-the-Art. Anticancer Research, 2022, 42, 3261-3274.	1.1	5
367	3D-PAST: Risk Assessment Model for Predicting Venous Thromboembolism in COVID-19. Journal of Clinical Medicine, 2022, 11, 3949.	2.4	2
368	Illustrated State-of-the-Art Capsules of the ISTH 2022 Congress. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12747.	2.3	4

#	ARTICLE	IF	CITATIONS
369	Good practice statements for antithrombotic therapy in the management of COVID-19: Guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2226-2236.	3.8	23
370	Anticoagulants for thrombosis prophylaxis in acutely ill patients admitted to hospital: systematic review and network meta-analysis. <i>BMJ</i> , The, 0, , e070022.	6.0	7
371	A Prospective Study Evaluating Cumulative Incidence and a Specific Prediction Rule in Pulmonary Embolism in COVID-19. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	8
372	The interplay between inflammation and thrombosis in COVID-19: Mechanisms, therapeutic strategies, and challenges. <i>Thrombosis Update</i> , 2022, 8, 100117.	0.9	1
373	Outcomes of COVID-19 in a Large Cohort of Lung Transplant Recipients: A Retrospective Study. <i>Transplantology</i> , 2022, 3, 257-266.	0.6	1
374	Bleeding and thrombotic complications in patients with severe COVID-19: A prospective observational study. <i>Health Science Reports</i> , 2022, 5, .	1.5	3
375	Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper. <i>Journal of Hepatology</i> , 2022, 77, 1161-1197.	3.7	46
376	Beta receptor blocker therapy for the elderly in the COVID-19 era. <i>World Journal of Clinical Cases</i> , 2022, 10, 8088-8096.	0.8	2
377	Adoption and Deadoption of Medications to Treat Hospitalized Patients With COVID-19. , 2022, 4, e0727.		3
378	Early antithrombotic post-discharge therapy using prophylactic DOAC or dipyridamole improves long-term survival and cardiovascular outcomes in hospitalized COVID-19 survivors. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	9
379	Immunomodulation and endothelial barrier protection mediate the association between oral imatinib and mortality in hospitalised COVID-19 patients. <i>European Respiratory Journal</i> , 2022, 60, 2200780.	6.7	15
380	Therapeutic Approaches to the Neurologic Manifestations of COVID-19. <i>Neurotherapeutics</i> , 2022, 19, 1435-1466.	4.4	22
381	Applying Lessons Learned From COVID-19 Therapeutic Trials to Improve Future ALI/ARDS Trials. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	6
382	Patients with myeloproliferative neoplasms and COVID-19 have increased rates of arterial thrombosis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12752.	2.3	3
383	Biomarker derived risk scores predict venous thromboembolism and major bleeding among patients with COVID-19. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, .	2.3	1
384	Treatment of COVID-19 Pneumonia and Acute Respiratory Distress With Ramatroban, a Thromboxane A2 and Prostaglandin D2 Receptor Antagonist: A Four-Patient Case Series Report. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	8
385	Effect of tocilizumab, sarilumab, and baricitinib on mortality among patients hospitalized for COVID-19 treated with corticosteroids: a systematic review and meta-analysis. <i>Clinical Microbiology and Infection</i> , 2023, 29, 13-21.	6.0	19
386	Factors Modulating COVID-19: A Mechanistic Understanding Based on the Adverse Outcome Pathway Framework. <i>Journal of Clinical Medicine</i> , 2022, 11, 4464.	2.4	13

#	ARTICLE	IF	CITATIONS
387	Thromboprophylaxis for children hospitalized with COVID-19 and MISâ€C. Research and Practice in Thrombosis and Haemostasis, 2022, 6, .	2.3	6
388	Does high-dose thromboprophylaxis improve outcomes in COVID-19 patients? A meta-analysis of comparative studies. TH Open, 0, , .	1.4	1
389	Coagulopathy in COVID-19 and anticoagulation clinical trials. Best Practice and Research in Clinical Haematology, 2022, 35, 101377.	1.7	3
390	Cardiovascular Complications of Pregnancy-Associated COVID-19 Infections. , 2022, 1, 100057.		6
391	Ability of IMPROVE and IMPROVE-DD scores to predict outcomes in patients with severe COVID-19: a prospective observational study. Scientific Reports, 2022, 12, .	3.3	1
392	Otolaryngology consultations for COVID-19 patients: A retrospective cohort study of indications, interventions, and considerations. Auris Nasus Larynx, 2022, , .	1.2	0
393	Empiric Anticoagulation Therapy in Hospitalized COVID-19 Patients: An Evaluation of Bleeding Risk Scores Performances in Predicting Bleeding Events. Journal of Clinical Medicine, 2022, 11, 4965.	2.4	2
394	Preadmission Oral Anticoagulation for Atrial Fibrillation/Flutter and Death or Thrombotic Events During COVID-19 Admission. American Journal of Cardiology, 2022, 181, 38-44.	1.6	3
395	Effect of therapeutic versus prophylactic anticoagulation therapy on clinical outcomes in COVID-19 patients: a systematic review with an updated meta-analysis. Thrombosis Journal, 2022, 20, .	2.1	3
396	The pharmacology of anticoagulant drug treatment options in COVID-19 patients: reviewing real-world evidence in clinical practice. Expert Review of Clinical Pharmacology, 2022, 15, 1095-1105.	3.1	2
397	Incidence of thromboembolic complications in hospitalized COVID-19 patients in a medical ward in Japan: A single-center retrospective and prospective observational study. Medicine (United States), 2022, 101, e29933.	1.0	0
399	Care of the Seriously Ill Patient with SARS CoV-2. Medical Clinics of North America, 2022, , .	2.5	1
400	Long COVID endotheliopathy: hypothesized mechanisms and potential therapeutic approaches. Journal of Clinical Investigation, 2022, 132, .	8.2	76
401	A comparison of three thromboprophylaxis regimens in critically ill COVID-19 patients: An analysis of real-world data. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	0
402	Antithrombotiques chez les patients atteints de COVID-19. Cmaj, 2022, 194, E1074-E1075.	2.0	0
403	Coronavirus Disease 2019-Associated Coagulopathy. Microorganisms, 2022, 10, 1556.	3.6	8
404	Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19. Microorganisms, 2022, 10, 1639.	3.6	5
405	Deep Learningâ€‘Based Time-to-Death Prediction Model for COVID-19 Patients Using Clinical Data and Chest Radiographs. Journal of Digital Imaging, 2023, 36, 178-188.	2.9	6

#	ARTICLE	IF	CITATIONS
406	Low molecular weight heparin is associated with better outcomes than unfractionated heparin for thromboprophylaxis in hospitalized COVID-19 patients: a meta-analysis. European Heart Journal Quality of Care & Clinical Outcomes, 0, , .	4.0	1
407	The cross-talk of lung and heart complications in COVID-19: Endothelial cells dysfunction, thrombosis, and treatment. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	5
408	Thromboprophylaxis with standard-dose vs. flexible-dose heparin for hospitalized COVID-19 patients: a target trial emulation. Journal of Clinical Epidemiology, 2022, 151, 96-103.	5.0	5
409	Therapeutic versus prophylactic heparin for thromboprophylaxis in patients with COVID-19: weighing the costs and benefits. A rapid meta-analysis of randomized controlled trials. Archives of Medical Sciences Atherosclerotic Diseases, 2022, 7, 60-62.	1.0	0
410	Plasma biomarkers associated with survival and thrombosis in hospitalized COVID-19 patients. International Journal of Hematology, 2022, 116, 937-946.	1.6	11
411	Efficacy and safety of heparin full-dose anticoagulation in hospitalized non-critically ill COVID-19 patients: a meta-analysis of multicenter randomized controlled trials. Journal of Thrombosis and Thrombolysis, 2022, 54, 420-430.	2.1	17
412	Supportive Care in Patients with Critical COVID-19. Infectious Disease Clinics of North America, 2022, , .	5.1	0
413	Expert consensus on the diagnosis and treatment of severe and critical coronavirus disease 2019 (COVID-19). Journal of Intensive Medicine, 2022, 2, 199-222.	2.1	3
414	A systematic review of biomarkers among hospitalized patients with <scp>COVID</scp> â€19 predictive of venous thromboembolism: A communication from the Predictive and Diagnostic Variables <scp>Scientific and Standardization Committee</scp> of the <scp>ISTH</scp>. Research and Practice in Thrombosis and Haemostasis, 2022, 6, .	2.3	3
415	Novel Strategies for the Treatment of COVID-19. Drugs in R and D, 2022, 22, 257-262.	2.2	5
416	Pulmonary embolism in a patient with eltrombopag-treated aplastic anaemia and paroxysmal nocturnal haemoglobinuria clone during COVID-19 pneumonia. Thrombosis Journal, 2022, 20, .	2.1	7
417	Diffuse alveolar damage patterns reflect the immunological and molecular heterogeneity in fatal COVID-19. EBioMedicine, 2022, 83, 104229.	6.1	13
418	Venous Thromboembolic Disease in COVID-19, Pathophysiology, Therapy and Prophylaxis. International Journal of Molecular Sciences, 2022, 23, 10372.	4.1	3
419	Occurrence of Thromboembolic Events and Mortality Among Hospitalized Coronavirus 2019 Patients: Large Observational Cohort Study of Electronic Health Records. TH Open, 2022, 06, e408-e420.	1.4	5
421	Clinical, laboratory and immunohistochemical characterization of in situ pulmonary arterial thrombosis in fatal COVID-19. Thrombosis Research, 2022, 219, 95-101.	1.7	5
422	Anticoagulation in COVID-19 patients â€“ An updated systematic review and meta-analysis. Thrombosis Research, 2022, 219, 40-48.	1.7	12
423	Effect of combining anticoagulant and glucocorticoid therapy on mortality in patients with severe COVID-19. European Journal of Inflammation, 2022, 20, 1721727X2211009.	0.5	0
424	Early prophylactic anticoagulation with heparin alleviates mortality in critically ill patients with sepsis: a retrospective analysis from the MIMIC-IV database. Burns and Trauma, 2022, 10, .	4.9	7

#	ARTICLE	IF	CITATIONS
425	Letter to the Editor: Venous Thromboembolism in COVID-19: Are Women Different?. Indian Journal of Cardiovascular Disease in Women WINCARS, 0, 07, 007-008.	0.1	0
426	Anti-Xa Directed Thromboprophylaxis in Critically Ill Patients with Coronavirus Disease 2019. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962211163.	1.7	2
427	The diverse role of heparan sulfate and other GAGs in SARS-CoV-2 infections and therapeutics. Carbohydrate Polymers, 2023, 299, 120167.	10.2	8
428	Strategies for Cardio-Oncology Care During the COVID-19 Pandemic. Current Treatment Options in Cardiovascular Medicine, 2022, 24, 137-153.	0.9	2
429	Use of anticoagulants in patients with COVID-19: a living systematic review and meta-analysis. Jornal Brasileiro De Pneumologia, 0, , e20220041.	0.7	3
430	Standardization of D-dimer reporting in the COVID-19 era. Research and Practice in Thrombosis and Haemostasis, 2022, 6, .	2.3	1
431	Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients With COVID-19: COVID-PACT. Circulation, 2022, 146, 1344-1356.	1.6	39
432	Evolution of Approaches to Therapeutic Prevention and Treatment of the New Coronavirus Infection. Herald of the Russian Academy of Sciences, 2022, 92, 430-436.	0.6	0
433	A novel anticoagulation treatment protocol using unfractionated heparin for coronavirus disease 2019 patients in Japan, 2022. Global Health & Medicine, 2022, 4, 233-236.	1.4	1
434	Rotational thromboelastometry in critically ill COVID-19 patients does not predict thrombosis. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12798.	2.3	3
435	COVID-19: Opportunities to Improve Prognosis. Herald of the Russian Academy of Sciences, 2022, 92, 404-411.	0.6	1
436	Anticoagulation Strategies during Extracorporeal Membrane Oxygenation: A Narrative Review. Journal of Clinical Medicine, 2022, 11, 5147.	2.4	28
437	Thrombosis after SARS-CoV2 infection or COVID-19 vaccination: will a nonpathologic anti-PF4 antibody be a solution? A narrative review. Journal of Bio-X Research, 2022, 5, 97-103.	0.2	1
438	COVID-19-Related ARDS: Key Mechanistic Features and Treatments. Journal of Clinical Medicine, 2022, 11, 4896.	2.4	15
439	Is It Time to Revisit Remdesivir Use for Severe COVID-19?. Indian Journal of Critical Care Medicine, 2022, 26, 983-984.	0.9	2
440	Coronavirus disease 2019 subphenotypes and differential treatment response to convalescent plasma in critically ill adults: secondary analyses of a randomized clinical trial. Intensive Care Medicine, 2022, 48, 1525-1538.	8.2	13
441	Intrapulmonary shunt and alveolar dead space in a cohort of patients with acute COVID-19 pneumonitis and early recovery. European Respiratory Journal, 2023, 61, 2201117.	6.7	8
442	Approach to Thromboprophylaxis for Prevention of Venous Thromboembolism in COVID-19: Global Updates and Clinical Insights from India. Clinics and Practice, 2022, 12, 766-781.	1.4	2

#	ARTICLE	IF	CITATIONS
443	Efficacy and Safety of Tinzaparin in Prophylactic, Intermediate and Therapeutic Doses in Non-Critically Ill Patients Hospitalized with COVID-19: The PROTHROMCOVID Randomized Controlled Trial. Journal of Clinical Medicine, 2022, 11, 5632.	2.4	5
444	Therapeutic-dose anticoagulation or thromboprophylaxis with low-molecular-weight heparin for moderate Covid-19: meta-analysis of randomized controlled trials. Clinical and Experimental Medicine, 0, , .	3.6	2
445	Which are the optimal thromboprophylaxis strategies for hospitalized patients with COVID-19? current controversies. Vascular, 2024, 32, 220-225.	0.9	0
446	Correlating drug prescriptions with prognosis in severe COVID-19: first step towards resource management. BMC Medical Informatics and Decision Making, 2022, 22, .	3.0	1
447	The Case for Therapeutic-Intensity Anticoagulation in Patients with COVID-19-Associated Moderate Illness. Seminars in Thrombosis and Hemostasis, 2023, 49, 076-078.	2.7	4
448	Traumatic brain injury: progress and challenges in prevention, clinical care, and research. Lancet Neurology, The, 2022, 21, 1004-1060.	10.2	197
449	Saving millions of lives but some resources squandered: emerging lessons from health research system pandemic achievements and challenges. Health Research Policy and Systems, 2022, 20, .	2.8	5
450	Higher Dose Anticoagulation Cannot Prevent Disease Progression in COVID-19 Patients: A Systematic Review and Meta-Analysis. Biomedicines, 2022, 10, 2194.	3.2	0
451	Development and Implementation of the National Heart, Lung, and Blood Institute COVID-19 Common Data Elements. Journal of Clinical and Translational Science, 0, , 1-25.	0.6	0
452	Heart failure during the COVID-19 pandemic: clinical, diagnostic, management, and organizational dilemmas. ESC Heart Failure, 2022, 9, 3713-3736.	3.1	12
453	AMMI Canada Practice Point: Treatments for adults with COVID-19 in 2021-2022. Jammi, 2022, 7, 163-169.	0.5	0
454	Use of low molecular weight heparin and hemoglobin fall in COVID-19 patients: A STROBE-compliant study. Medicine (United States), 2022, 101, e30367.	1.0	0
455	Life-threatening retroperitoneal bleeding in coronavirus disease 2019 patient while on full dose anticoagulation: A case report. International Journal of Case Reports and Images, 2022, 13, 86-90.	0.0	0
456	Hydroxychloroquine, azithromycin and methylprednisolone and in hospital survival in severe COVID-19 pneumonia. Frontiers in Pharmacology, 0, 13, .	3.5	1
458	Respiratory Comorbidity and Pulmonary Embolism. Archivos De Bronconeumologia, 2023, 59, 131-133.	0.8	1
459	C-reactive protein, immunothrombosis and venous thromboembolism. Frontiers in Immunology, 0, 13, .	4.8	21
460	Failed clinical trials on COVID-19 acute respiratory distress syndrome in hospitalized patients: common oversights and streamlining the development of clinically effective therapeutics. Expert Opinion on Investigational Drugs, 2022, 31, 995-1015.	4.1	4
461	COVID-19 outcomes in sickle cell disease and sickle cell trait. Best Practice and Research in Clinical Haematology, 2022, 35, 101382.	1.7	1

#	ARTICLE	IF	CITATIONS
462	Predictors of fatal neurological complications among admitted COVID-19 patients with their implication in outcome: A Case Control study. PLoS ONE, 2022, 17, e0274485.	2.5	1
463	COVID-19 Thrombotic Complications and Therapeutic Strategies. Annual Review of Medicine, 2023, 74, 15-30.	12.2	4
464	Pulmonary Vascular Thrombosis in COVID-19: Clinical and Morphological Parallels. Rational Pharmacotherapy in Cardiology, 2022, 18, 376-384.	0.8	3
465	Antiplatelet therapy for patients with COVID-19: Systematic review and meta-analysis of observational studies and randomized controlled trials. Frontiers in Medicine, 0, 9, .	2.6	10
466	The optimal anticoagulation strategy for COVID-19, prophylactic or therapeutic?: a meta-analysis, trial sequential analysis, and meta-regression of more than 27,000 participants. , 2022, 2, 148-166.		0
467	Incidence, risk factors, and clinical impact of major bleeding in hospitalized patients with COVID-19: a sub-analysis of the CLOT-COVID Study. Thrombosis Journal, 2022, 20, .	2.1	7
468	Care for adults with <scp>COVID</scp> â€19: living guidelines from the National <scp>COVID</scp> â€19 Clinical Evidence Taskforce. Medical Journal of Australia, 2022, 217, 368-378.	1.7	8
469	Prevalence of Venous Thromboembolism and Anticoagulant Use in Patients with COVID-19 in Alberta, Canada. Canadian Journal of Hospital Pharmacy, 2022, 75, 286-293.	0.1	0
470	Knowledge Gaps for Prophylactic Use of Antithrombotic Agents in Patients with COVID-19: Insights into New SARS-CoV-2 Variants, Vaccination Status, and Emerging Oral Antivirals. Thrombosis and Haemostasis, 2023, 123, 186-191.	3.4	4
471	Current practices in pediatric hospitalâ€acquired thromboembolism: Survey of the Children's Hospital Acquired Thrombosis (CHAT) Consortium. Research and Practice in Thrombosis and Haemostasis, 2022, 6, .	2.3	0
473	The Comparison of Therapeutic With Prophylactic Anticoagulation on Mortality, Risk of Bleeding, and Thromboembolism in Hospitalized Patients With COVID-19: A Systematic Review. Cureus, 2022, , .	0.5	1
474	In-hospital Mortality Rates in SARS-CoV-2 Patients Treated with Enoxaparin and Heparin. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962211318.	1.7	1
475	Japanese rapid/living recommendations on drug management for <scp>COVID</scp> â€19: updated guidelines (July 2022). Acute Medicine & Surgery, 2022, 9, .	1.2	6
476	Tissue plasminogen activator resistance is an early predictor of posttraumatic venous thromboembolism: A prospective study from the CLOTT research group. Journal of Trauma and Acute Care Surgery, 2022, 93, 597-603.	2.1	9
477	â€â€ <scp>ISTH</scp> guidelines for antithrombotic treatment in COVIDâ€19â€. Reply. Journal of Thrombosis and Haemostasis, 2022, 20, 2710-2711.	3.8	3
478	Trough anti-Xa activity after intermediate dose nadroparin for thrombosis prophylaxis in critically ill patients with COVID-19 and acute kidney injury. Scientific Reports, 2022, 12, .	3.3	0
479	Long pentraxin 3 (PTX3) levels predict death, intubation and thrombotic events among hospitalized patients with COVID-19. Frontiers in Immunology, 0, 13, .	4.8	5
480	From Cytokine Storm to Cytokine Breeze: Did Lessons Learned from Immunopathogenesis Improve Immunomodulatory Treatment of Moderate-to-Severe COVID-19?. Biomedicines, 2022, 10, 2620.	3.2	6

#	ARTICLE	IF	CITATIONS
481	Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial. <i>Lancet Respiratory Medicine</i> , 2022, 10, 1169-1177.	10.7	14
482	Venous thromboembolism in critically ill patients with pneumonia in the <scp>preâ€COVID</scp> â€19 era: Data from a large public database. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, .	2.3	0
483	Clinical Differences and Outcomes of COVID-19 Associated Pulmonary Thromboembolism in Comparison with Non-COVID-19 Pulmonary Thromboembolism. <i>Journal of Clinical Medicine</i> , 2022, 11, 6011.	2.4	2
484	Incidence of Venous Thromboembolism in Hospitalized COVID-19 Patients Receiving Thromboprophylaxis. <i>Journal of Hematology (Brossard, Quebec)</i> , 2022, 11, 167-175.	1.0	0
485	Investigation of the pharmacokinetic properties of synthetic heparan sulfate oligosaccharides. <i>Glycobiology</i> , 0, , .	2.5	1
486	Mortality risk factors in patients with SARS-CoV-2 infection and atrial fibrillation: Data from the SEMI-COVID-19 registry. <i>Medicina Clínica (English Edition)</i> , 2022, 159, 457-464.	0.2	0
487	Pharmacologic therapies of ARDS: From natural herb to nanomedicine. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	4
488	Subgroup analyses in venous thromboembolism trials reporting pharmacological interventions: A systematic review. <i>Thrombosis Research</i> , 2023, 232, 151-159.	1.7	1
489	COVID-19-Associated Pulmonary Embolism: Review of the Pathophysiology, Epidemiology, Prevention, Diagnosis, and Treatment. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 816-832.	2.7	12
490	Inflammatory and Hemostatic Markers in COVID-19 Patients with Arterial Thrombosis Are Significantly Lower at Hospital Admission than in COVID-19 Patients without Thrombosis. <i>Viruses</i> , 2022, 14, 2330.	3.3	0
491	Drugs for the prevention and treatment of COVID-19 and its complications: An update on what we learned in the past 2 years. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	8
492	Therapeutic advances in COVID-19. <i>Nature Reviews Nephrology</i> , 2023, 19, 38-52.	9.6	67
493	Practical Recommendations for Optimal Thromboprophylaxis in Patients with COVID-19: A Consensus Statement Based on Available Clinical Trials. <i>Journal of Clinical Medicine</i> , 2022, 11, 5997.	2.4	13
494	Bivalirudin vs. Enoxaparin in Intubated COVID-19 Patients: A Pilot Multicenter Randomized Controlled Trial. <i>Journal of Clinical Medicine</i> , 2022, 11, 5992.	2.4	2
495	Step up to the platelet: Role of platelets in inflammation and infection. <i>Thrombosis Research</i> , 2023, 231, 182-194.	1.7	6
496	Association between Thrombin Generation and Clinical Characteristics in COVID-19 Patients. <i>Acta Haematologica</i> , 2023, 146, 151-160.	1.4	0
497	COVID-19 Therapeutics and Considerations for Pregnancy. <i>Obstetrics and Gynecology Clinics of North America</i> , 2022, , .	1.9	0
499	Thromboembolic and bleeding events in <scp>ICU</scp> patients with <scp>COVID</scp> â€19 â€a nationwide, observational study. <i>Acta Anaesthesiologica Scandinavica</i> , 0, , .	1.6	3

#	ARTICLE	IF	CITATIONS
500	Modulation of thromboinflammation in hospitalized COVID-19 patients with aprotinin, low molecular weight heparin, and anakinra: The DAWN- antico study. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12826.	2.3	2
501	Evaluation of a fast and frugal clinical decision algorithm (â€˜pathwaysâ€™™) on clinical outcomes in hospitalised patients with COVID-19 treated with anticoagulants. Journal of Evaluation in Clinical Practice, 2023, 29, 3-12.	1.8	3
502	Indian Society of Critical Care Medicine Consensus Statement for Prevention of Venous Thromboembolism in the Critical Care Unit. Indian Journal of Critical Care Medicine, 2022, 26, S51-S65.	0.9	0
503	Evaluating Risk: Benefit Ratio of Fat-Soluble Vitamin Supplementation to SARS-CoV-2-Infected Autoimmune and Cancer Patients: Do Vitamin-Drug Interactions Exist?. Life, 2022, 12, 1654.	2.4	1
504	Machine Learning Approaches for Phenotyping in Cardiogenic Shock and Critical Illness. , 2022, 1, 100126.		8
505	Assessment of Healthcare Resource Utilization by Anticoagulant Heparinoid Dosage Level in Patients Hospitalized with COVID-19. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962211378.	1.7	0
506	Prevalence and Risk Factors of Venous Thromboembolism in Critically Ill Patients with Severe COVID-19 and the Association between the Dose of Anticoagulants and Outcomes. The Journal of Critical Care Medicine, 2022, 8, 249-258.	0.7	0
509	COVID-19 in Russia: Evolution of Views on the Pandemic. Report II. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 2022, 77, 291-306.	0.6	2
510	Intensity of anticoagulant dosing in hospitalized patients with COVID-19: an observational, comparative effectiveness study. Journal of Hospital Medicine, 0, , .	1.4	1
511	Analysis of Prior Aspirin Treatment on in-Hospital Outcome of Geriatric COVID-19 Infected Patients. Medicina (Lithuania), 2022, 58, 1649.	2.0	0
512	Therapeutic considerations for prevention and treatment of thrombotic events in COVID-19. Thrombosis Update, 2022, , 100126.	0.9	0
513	Lung Transplantation for COVID-19 patients and COVID-19 in Lung Transplant Recipients. Clinics in Chest Medicine, 2022, , .	2.1	0
514	Pathophysiological mechanisms of thrombosis in acute and long COVID-19. Frontiers in Immunology, 0, 13, .	4.8	24
515	Life stressors significantly impact long-term outcomes and post-acute symptoms 12-months after COVID-19 hospitalization. Journal of the Neurological Sciences, 2022, 443, 120487.	0.6	13
516	Promising Drug Fondaparinux for the Treatment of COVID-19: an In Silico Analysis of Low Molecular Weight Heparin, Direct Oral Anticoagulant, and Antiplatelet Drug Interactions with Host Protease Furin. Cardiovascular Drugs and Therapy, 0, , .	2.6	1
517	Characteristics of subarachnoid hemorrhage associated with COVID-19 infection: A systematic review and descriptive analysis. Journal of Stroke and Cerebrovascular Diseases, 2023, 32, 106904.	1.6	1
518	COVID-19 signalome: Potential therapeutic interventions. Cellular Signalling, 2023, 103, 110559.	3.6	5
519	COVID-19 pandemic: the impact on Canadaâ€™s intensive care units. Facets, 2022, 7, 1411-1472.	2.4	3

#	ARTICLE	IF	CITATIONS
520	COVID-19 IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS: THE RISK OF THROMBOEMBOLIC EVENTS AND CURRENT OPTIONS FOR ANTITHROMBOTIC PROPHYLAXIS. , 2022, , 88-103.	0.1	0
521	Practice of Awake Prone Positioning in Critically Ill COVID-19 Patientsâ€”Insights from the PRoAcTâ€”COVID Study. Journal of Clinical Medicine, 2022, 11, 6988.	2.4	2
522	Characteristics and Outcomes of Critically Ill Pregnant/Postpartum Women with COVID-19 Pneumonia in Western Balkans, The Republic of Srpska Report. Medicina (Lithuania), 2022, 58, 1730.	2.0	2
523	COVID-19 and Pulmonary Thrombosisâ€”An Unresolved Clinical Puzzle: A Single-Center Cohort Study. Journal of Clinical Medicine, 2022, 11, 7049.	2.4	3
524	Impact of COVID-19 on Non-Pulmonary Critical Illness: Prevalence, Clinical Manifestations, Management, and Outcomes. Clinics in Chest Medicine, 2022, , .	2.1	0
525	Hypercoagulability in critically ill patients with COVID 19, an observational prospective study. PLoS ONE, 2022, 17, e0277544.	2.5	5
526	Pathophysiology of Hypoxemia in COVID-19 Lung Disease. Clinics in Chest Medicine, 2023, 44, 239-248.	2.1	3
527	Challenges in evaluating treatments for COVID-19: The case of in-hospital anticoagulant use and the risk of adverse outcomes. Frontiers in Pharmacology, 0, 13, .	3.5	0
528	Platform trials for anaesthesia and perioperative medicine: a narrative review. British Journal of Anaesthesia, 2023, 130, 677-686.	3.4	3
530	How to use and report data on Dâ€šdimer testing in the <scp>COVID</scp> â€”19 era?. Research and Practice in Thrombosis and Haemostasis, 2022, 6, .	2.3	0
531	Pathological Lung Patterns of COVID-19 and its Clinical Correlation to Disease Severity. Indian Journal of Critical Care Medicine, 2022, 26, 1285-1292.	0.9	2
532	Temporal Improvements in COVID-19 Outcomes for Hospitalized Adults: A Post Hoc Observational Study of Remdesivir Group Participants in the Adaptive COVID-19 Treatment Trial. Annals of Internal Medicine, 2022, 175, 1716-1727.	3.9	2
533	Treatment of pregnant and early postpartum women with severe and critical COVID-19: experience at a tertiary center. European Journal of Medical Research, 2022, 27, .	2.2	1
535	The Effectiveness of the Intermediate and Therapeutic Doses of Enoxaparin in COVID-19 Patients: A Comparative Study of Factor Xa Inhibition. Acta Haematologica, 2023, 146, 137-143.	1.4	0
536	The Histone Methyltransferase MLL1/KMT2A in Monocytes Drives Coronavirus-Associated Coagulopathy and Inflammation. Blood, 0, , .	1.4	2
537	A leap towards personalised therapy of acute lung injury. European Respiratory Journal, 2022, 60, 2201808.	6.7	1
538	Changes in anticoagulant and antiplatelet drug supply at US hospitals before and during the COVID-19 pandemic (2018-2021). American Journal of Health-System Pharmacy, 0, , .	1.0	0
539	Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial. JAMA - Journal of the American Medical Association, 2023, 329, 39.	7.4	64

#	ARTICLE	IF	CITATIONS
540	Safety and efficacy of prophylactic anticoagulation versus therapeutic anticoagulation in hospital-admitted COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials. <i>Clinical Respiratory Journal</i> , 2023, 17, 73-79.	1.6	3
541	ASCOT ADAPT study of COVID-19 therapeutics in hospitalised patients: an international multicentre adaptive platform trial. <i>Trials</i> , 2022, 23, .	1.6	4
543	AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants. <i>European Journal of Cancer</i> , 2023, 181, 102-118.	2.8	2
544	COVID-19 and Pulmonary Embolism Outcomes among Hospitalized Patients in the United States: A Propensity-Matched Analysis of National Inpatient Sample. <i>Vaccines</i> , 2022, 10, 2104.	4.4	4
545	Identification of two specific transcriptomic clusters of COVID-19 ARDS patients with different immune profiles and different outcomes. <i>European Respiratory Journal</i> , 0, , 2202008.	6.7	0
547	COVID-19 drug-induced liver injury: A recent update of the literature. <i>World Journal of Gastroenterology</i> , 0, 28, 6314-6327.	3.3	5
548	Thrombosis questions from the inpatient wards. <i>Hematology American Society of Hematology Education Program</i> , 2022, 2022, 481-490.	2.5	1
549	Population pharmacokinetics of nadroparin for thromboprophylaxis in COVID-19 intensive care unit patients. <i>British Journal of Clinical Pharmacology</i> , 2023, 89, 1617-1628.	2.4	3
550	Anticoagulation Strategies in Non-Critically Ill Patients with Covid-19. , 2023, 2, .		5
551	To prophylax or not, and how much and how long? Controversies in VTE prevention for medical inpatients, including COVID-19 inpatients. <i>Hematology American Society of Hematology Education Program</i> , 2022, 2022, 506-514.	2.5	4
552	Gaps and opportunities in sepsis translational research. <i>EBioMedicine</i> , 2022, 86, 104387.	6.1	6
553	Long-term Follow-up After Critical COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 0, , .	7.4	4
554	Major Publications in the Critical Care Pharmacotherapy Literature: 2021. , 2022, 4, e0823.		1
555	Downregulation of the Protein C Signaling System Is Associated with COVID-19 Hypercoagulability-A Single-Cell Transcriptomics Analysis. <i>Viruses</i> , 2022, 14, 2753.	3.3	3
556	Post-discharge Thromboembolic Events in COVID-19 Patients: A Review on the Necessity for Prophylaxis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2023, 29, 107602962211484.	1.7	5
557	Effect of a systematic lung-protective protocol for COVID-19 pneumonia requiring invasive ventilation: A single center retrospective study. <i>PLoS ONE</i> , 2023, 18, e0267339.	2.5	0
558	Pulmonary Embolism After COVID-19 (Epidemiology, Influence on Prognosis, Pathogenesis, Treatment). <i>Contemporary Cardiology</i> , 2022, , 243-254.	0.1	0
559	Multi-marker risk assessment in patients hospitalized with COVID-19: Results from the American Heart Association COVID-19 Cardiovascular Disease Registry. <i>American Heart Journal</i> , 2023, 258, 149-156.	2.7	3

#	ARTICLE	IF	CITATIONS
560	Microvascular significance of TGF- β 2 axis activation in COVID-19. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	11
561	Risk Factors and Impact on Outcomes of Thrombosis in Patients with COVID-19 in Japan: From the CLOT-COVID Study. <i>Annals of Vascular Diseases</i> , 2023, , .	0.5	0
562	Models for Evidence Generation During the COVID-19 Pandemic: New Opportunities for Clinical Trials in Cardiovascular Medicine. <i>Circulation</i> , 2023, 147, 187-189.	1.6	4
563	A Review of Coronavirus Disease 2019 in Pregnancy. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2023, 44, 050-065.	2.1	0
564	Reply to Bareille et al. Are Viscoelastometric Assays of Old Generation Ready for Disposal? Comment on "Volod et al. Viscoelastic Hemostatic Assays: A Primer on Legacy and New Generation Devices. <i>J. Clin. Med.</i> 2022, 11, 860". <i>Journal of Clinical Medicine</i> , 2023, 12, 478.	2.4	1
565	Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: Multilayered cross-talks in the setting of coinfections and comorbidities. <i>PLoS Pathogens</i> , 2023, 19, e1011063.	4.7	7
566	Predictive Value of Echocardiographic Pulmonary to Left Atrial Ratio for In-Hospital Death in Patients with COVID-19. <i>Diagnostics</i> , 2023, 13, 224.	2.6	0
567	Perspective Chapter: Cardiovascular Post-Acute COVID-19 Syndrome "Definition, Clinical Scenarios, Diagnosis, and Management. , 0, , .		1
569	Efficacy and safety of two heparin regimens for prevention of venous thromboembolism in hospitalized patients with COVID-19: a meta-analysis. <i>Internal and Emergency Medicine</i> , 2023, 18, 863-877.	2.0	2
570	Omicron, Long-COVID, and the Safety of Elective Surgery for Adults and Children: Joint Guidance from the Therapeutics and Guidelines Committee of the Surgical Infection Society and the Surgery Strategic Clinical Network, Alberta Health Services. <i>Surgical Infections</i> , 2023, 24, 6-18.	1.4	4
571	Acute Mesenteric Ischemia in COVID-19 While Receiving Prophylactic Enoxaparin. <i>Clinical Medicine and Research</i> , 2022, 20, 236-240.	0.8	1
573	Thromboprophylaxis in COVID-19. <i>Medicina Interna (Bucharest, Romania)</i> , 2022, 19, 59-69.	0.0	0
575	Network pharmacology- and molecular simulation-based exploration of therapeutic targets and mechanisms of heparin for the treatment of sepsis/COVID-19. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 12586-12598.	3.5	5
576	Antithrombotic therapy in COVID-19 patients. <i>Obstetrics, Gynecology and Reproduction</i> , 2023, 16, 718-731.	0.5	1
577	Mechanisms of impaired alveolar fluid clearance. <i>Anatomical Record</i> , 0, , .	1.4	2
578	Chronic anti-coagulation therapy reduced mortality in patients with high cardiovascular risk early in COVID-19 pandemic. <i>Thrombosis Journal</i> , 2023, 21, .	2.1	0
579	COVID-19 and atrial fibrillation: Intercepting lines. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	2.4	11
580	Enoxaparin Posology According to Prothrombotic Status and Bleeding Risk in Hospitalized Patients with SARS-CoV-2 Pneumonia. <i>Journal of Clinical Medicine</i> , 2023, 12, 928.	2.4	0

#	ARTICLE	IF	CITATIONS
581	Electrical Impedance Tomography As a Bedside Diagnostic Tool for Pulmonary Embolism. , 2023, 5, e0843.		3
582	The Conundrum of Anticoagulation for Hospitalized Patients with Covid-19. , 2023, 2, .		0
583	Microvascular Thrombosis as a Critical Factor in Severe COVID-19. International Journal of Molecular Sciences, 2023, 24, 2492.	4.1	10
584	COVID-19 and Cavitory Lesion in Lung. Cureus, 2023, , .	0.5	2
585	Comparison of Preprint Postings of Randomized Clinical Trials on COVID-19 and Corresponding Published Journal Articles. JAMA Network Open, 2023, 6, e2253301.	5.9	0
586	Is perioperative COVID-19 really associated with worse surgical outcomes? A nationwide COVIDSurg propensity-matched analysis. Journal of Trauma and Acute Care Surgery, 2023, 94, 513-524.	2.1	5
587	A randomized controlled trial to evaluate outcomes with Aggrenox in patients with SARS-CoV-2 infection. PLoS ONE, 2023, 18, e0274243.	2.5	0
588	Distribution of aeration and pulmonary blood volume in healthy, ARDS and COVID-19 lungs: a dual-energy computed tomography retrospective cohort study. Academic Radiology, 2023, , .	2.5	0
589	The Collateral Benefit of COVID Pandemic: Improved Pharmacological Venous Thromboembolism Prophylaxis Practices in Non-COVID Patients. International Journal of General Medicine, 0, Volume 16, 1069-1079.	1.8	0
590	International platform trials: as diseases cross borders, so should trials. Lancet Infectious Diseases, The, 2023, 23, 530-531.	9.1	0
591	Effect of therapeutic anticoagulation on gas exchange in mechanically ventilated COVID-19 patients: A secondary analysis of the COVID-HEP trial. Thrombosis Research, 2023, 224, 13-16.	1.7	0
593	Thromboembolic Events in COVID-19. Contemporary Cardiology, 2022, , 201-216.	0.1	0
594	Thromboembolic events in hospitalised patients with COVID-19: ecological assessment with a scoping review. BMJ Open, 2023, 13, e066218.	1.9	3
595	FEATURES OF COAGULOPATHY AND SYSTEMIC INFLAMMATION IN PATIENTS AFTER COVID-19 INFECTION. WiadomoÅci Lekarskie, 2022, 75, 2907-2914.	0.3	0
596	The Efficacy and Safety of Prolonged Oral Anticoagulation for the Prevention of Thromboembolic Events in Patients Recovered From COVID-19 1 Year After Hospital Discharge: The SARCOV-19 Prospective Registry. Clinical and Applied Thrombosis/Hemostasis, 2023, 29, 107602962311517.	1.7	1
597	Incidence of lower limb deep vein thrombosis in patients with COVID-19 pneumonia through different waves of SARS-CoV-2 pandemic: A multicenter prospective study. PLoS ONE, 2023, 18, e0280247.	2.5	1
598	The Effect of Heparin Full-Dose Anticoagulation on Survival of Hospitalized, Non-critically Ill COVID-19 Patients: A Meta-analysis of High Quality Studies. Lung, 2023, 201, 135-147.	3.3	7
599	The intersection of obesity and (long) COVID-19: Hypoxia, thrombotic inflammation, and vascular endothelial injury. Frontiers in Cardiovascular Medicine, 0, 10, .	2.4	17

#	ARTICLE	IF	CITATIONS
600	Therapeutic options in COVID-19. , 2023, , 647-672.		0
601	MICHELLE trial: Inching towards the holy grail of post-discharge anticoagulation in Covid-19!. The National Medical Journal of India, 0, 35, 290-292.	0.3	0
602	Colchicine and high-intensity rosuvastatin in the treatment of non-critically ill patients hospitalised with COVID-19: a randomised clinical trial. BMJ Open, 2023, 13, e067910.	1.9	7
603	Extracardiac Prothrombotic Effects of COVID-19. Heart Failure Clinics, 2023, 19, 213-220.	2.1	0
604	An Emerging Role for Type I Interferons as Critical Regulators of Blood Coagulation. Cells, 2023, 12, 778.	4.1	6
607	Effects of 12Âmg vs. 6Âmg dexamethasone on thromboembolism and bleeding in patients with critical COVID-19 - a post hoc analysis of the randomized, blinded COVID STEROID 2 trial. Annals of Intensive Care, 2023, 13, .	4.6	1
608	Hemorrhage, Disseminated Intravascular Coagulopathy, and Thrombosis Complications Among Critically Ill Patients with COVID-19: An International COVID-19 Critical Care Consortium Study*. Critical Care Medicine, 2023, 51, 619-631.	0.9	7
609	Interactions between the reninâ€“angiotensinâ€“aldosterone system and COVID-19. , 2023, , 355-373.		0
610	Retroperitoneal hematoma: An unexpected complication of anticoagulant therapy in COVID-19 patients. Srpski Arhiv Za Celokupno Lekarstvo, 2023, , 23-23.	0.2	0
611	Utility of laboratory and immune biomarkers in predicting disease progression and mortality among patients with moderate to severe COVID-19 disease at a Philippine tertiary hospital. Frontiers in Immunology, 0, 14, .	4.8	0
612	Randomized Trial of Anticoagulation Strategies for Noncritically Ill Patients Hospitalized With COVID-19. Journal of the American College of Cardiology, 2023, 81, 1747-1762.	2.8	24
613	Treating COVID-19: Targeting the Host Response, Not the Virus. Life, 2023, 13, 712.	2.4	2
614	Thrombosis and bleeding in patients with COVID-19 requiring extracorporeal membrane oxygenation: a systematic review and meta-analysis. Research and Practice in Thrombosis and Haemostasis, 2023, 7, 100103.	2.3	4
615	Assessing the effects of therapeutic combinations on SARS-CoV-2 infected patient outcomes: A big data approach. PLoS ONE, 2023, 18, e0282587.	2.5	0
617	Novel mechanisms of thrombo-inflammation during infection: spotlight on neutrophil extracellular trap-mediated platelet activation. Research and Practice in Thrombosis and Haemostasis, 2023, 7, 100116.	2.3	11
618	Anti-cytokine Therapy in Critical Illness: Is There a Role?. Lessons From the ICU, 2023, , 277-297.	0.1	0
619	Atrial Fibrillation Occurring During Acute Hospitalization: A Scientific Statement From the American Heart Association. Circulation, 2023, 147, .	1.6	12
620	Assessment of the Risk of Venous Thromboembolism in Nonhospitalized Patients With COVID-19. JAMA Network Open, 2023, 6, e232338.	5.9	7

#	ARTICLE	IF	CITATIONS
621	The effect of anti-coagulation dosage on the outcome of hospitalized COVID-19 patients in Ethiopia: a multi-center retrospective cohort study. BMC Pulmonary Medicine, 2023, 23, .	2.0	0
622	COVID-19 Associated Micro-Anastomotic Thrombosis After Abdominal Free Tissue Transfer: A Case Report and Literature Review. Plastic Surgery, 0, , 229255032311610.	1.0	0
623	Safety and Efficacy of Different Anticoagulant Doses for Patients with COVID-19 in the ICU: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2023, 12, 2222.	2.4	0
624	Retrospective Study of Thrombosis in Hospitalized Patients with COVID-19 in Rural North Carolina. North Carolina Medical Journal, 2023, 84, .	0.2	0
625	Mechanisms of COVID-19 Associated Pulmonary Thrombosis: A Narrative Review. Biomedicines, 2023, 11, 929.	3.2	0
626	Immunothrombosis and COVID-19 â€” a nested post-hoc analysis from a 3186 patient cohort in a Latin American public reference hospital. Clinics, 2023, 78, 100178.	1.5	0
627	Rivaroxabana em Pacientes Ambulatoriais com COVID-19 Leve ou Moderada: FundamentaÃ§Ã£o e Desenho do Estudo CARE (CARE â€” Coalition COVID-19 Brazil VIII). Arquivos Brasileiros De Cardiologia, 2023, 120, .	0.8	1
628	Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19. JAMA - Journal of the American Medical Association, 2023, 329, 1066.	7.4	25
630	Effects of Standard-Dose Prophylactic, High-Dose Prophylactic, and Therapeutic Anticoagulation in Patients With Hypoxemic COVID-19 Pneumonia. JAMA Internal Medicine, 2023, 183, 520.	5.1	11
631	Anticoagulation in Patients With COVID-19 Pneumoniaâ€”What Is the Optimal Intensity?. JAMA Internal Medicine, 2023, 183, 532.	5.1	3
632	An Evolving Understanding of the Basis and Management of Vascular Complications of COVID-19: Where Do We Go From Here?. Canadian Journal of Cardiology, 2023, 39, 865-874.	1.7	2
633	Cellular and molecular features of COVID-19 associated ARDS: therapeutic relevance. Journal of Inflammation, 2023, 20, .	3.4	2
634	Neurologic Complications of Patients With COVID-19 Requiring Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-Analysis. , 2023, 5, e0887.		1
635	D-dimer testing: A narrative review. Advances in Clinical Chemistry, 2023, , 151-223.	3.7	1
636	Approaches to Assure Similarity between Pharmaceutical Heparins from Two Different Manufacturers. Pharmaceutics, 2023, 15, 1115.	4.5	2
637	Differences in clinical characteristics and quantitative lung CT features between vaccinated and not vaccinated hospitalized COVID-19 patients in Italy. Annals of Intensive Care, 2023, 13, .	4.6	2
638	Incidence of deep venous thrombosis in COVID-19 critically ill patients treated with intermediate-dose of heparin for thromboprophylaxis: The COVIDOP-DVT observational study. Vascular, 0, , 170853812311650.	0.9	0
639	Longitudinal Trends in Cardiovascular Risk Factor Profiles and Complications Among Patients Hospitalized for COVID-19 Infection: Results From the American Heart Association COVID-19 Cardiovascular Disease Registry. Circulation: Cardiovascular Quality and Outcomes, 2023, 16, .	2.2	2

#	ARTICLE	IF	CITATIONS
640	Treatment options for patients with severe COVID-19. <i>Global Health & Medicine</i> , 2023, 5, 99-105.	1.4	1
641	Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Supportâ€“Free Days in Patients Hospitalized With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2023, 329, 1183.	7.4	19
642	Ongoing Uncertainties in Bleeding and Clotting Complications in Patients With COVID-19*. <i>Critical Care Medicine</i> , 2023, 51, 688-691.	0.9	0
643	Dexamethasone Modulates the Cytokine Response but Not COVID-19-Induced Coagulopathy in Critically Ill. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7278.	4.1	4
644	Anticoagulation strategy and safety in critically ill COVID-19 patients: a French retrospective multicentre study. <i>Thrombosis Journal</i> , 2023, 21, .	2.1	0
646	Therapeutic strategies for COVID-19: progress and lessons learned. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 449-475.	46.4	112
647	Thrombosis Occurrence in COVID-19 Compared With Other Infectious Causes of ARDS: A Contemporary Cohort. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2023, 29, 107602962311756.	1.7	0
648	Population Pharmacokinetics and Probability of Target Attainment Analysis of Nadroparin in Different Stages of COVID-19. <i>Clinical Pharmacokinetics</i> , 2023, 62, 835-847.	3.5	1
649	Long-term post-acute sequelae of COVID-19 infection: a retrospective, multi-database cohort study in Hong Kong and the UK. <i>EClinicalMedicine</i> , 2023, 60, 102000.	7.1	27
650	Impact of thromboprophylaxis on hospital acquired thrombosis following discharge in patients admitted with <scp>COVID</scp>â€“19: Multicentre observational study in the <scp>UK</scp>. <i>British Journal of Haematology</i> , 2023, 202, 485-497.	2.5	3
651	Significance of heparin induced thrombocytopenia (HIT) in COVID-19: a systematic review and meta-analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2023, 56, 241-252.	2.1	2
652	A randomized controlled trial to investigate the use of acute coronary syndrome therapy in patients hospitalized with COVID-19: the COVID-19 Acute Coronary Syndrome trial. <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 2213-2222.	3.8	1
653	Clinical characteristics of COVID-19 associated vasculopathic diseases. <i>Thrombosis Journal</i> , 2023, 21, .	2.1	0
654	Optimal dosing of heparin for prophylactic anticoagulation in critically ill COVID-19 patients a systematic review and meta-analysis of randomized controlled trials. <i>Journal of Critical Care</i> , 2023, 77, 154344.	2.2	2
655	Effect of P2Y12 Inhibitors on Organ Supportâ€“Free Survival in Critically Ill Patients Hospitalized for COVID-19. <i>JAMA Network Open</i> , 2023, 6, e2314428.	5.9	4
656	Use of anticoagulants in patients with COVID-19: an update of a living systematic review and meta-analysis. <i>Jornal Brasileiro De Pneumologia</i> , 0, , e20230095.	0.7	0
657	Case report: Spontaneous hemothorax following anticoagulation for microthrombi in severe COVID pneumonia. <i>Respiratory Medicine Case Reports</i> , 2023, 44, 101864.	0.4	1
658	Continuation of therapeutic dose heparin for critically ill patients with COVID-19. <i>Intensive Care Medicine</i> , 2023, 49, 873-875.	8.2	3

#	ARTICLE	IF	CITATIONS
659	National Trends in Anticoagulation Therapy for COVID-19 Hospitalized Adults in the United States: Analyses of the National COVID Cohort Collaborative. <i>Journal of Infectious Diseases</i> , 0, , .	4.0	1
660	Role of Therapeutic Anticoagulation in COVID-19: The Current Situation. <i>Hematology Reports</i> , 2023, 15, 358-369.	0.8	4
661	Propensity-Score Matched Analysis of the Effectiveness of Baricitinib in Patients with COVID-19 Using Nationwide Real-World Data: An Observational Matched Cohort Study from The Japan COVID-19 Task Force. <i>Open Forum Infectious Diseases</i> , 0, , .	0.9	0
662	Low-molecular-weight heparin therapy reduces 28-day mortality in patients with sepsis-3 by improving inflammation and coagulopathy. <i>Frontiers in Medicine</i> , 0, 10, .	2.6	3
663	Effect of weight-adjusted intermediate-dose versus fixed-dose prophylactic anticoagulation with low-molecular-weight heparin on venous thromboembolism among noncritically and critically ill patients with COVID-19: the COVI-DOSE trial, a multicenter, randomised, open-label, phase 4 trial. <i>EClinicalMedicine</i> , 2023, 60, 102031.	7.1	6
664	Extra-cranial hemorrhagic complications in patients with COVID-19 infection: the experience of a secondary care COVID-19 institution. <i>Journal of Radiological Review</i> , 2023, 10, .	0.1	0
665	COVID-19 and Hematopoietic Stem Cell Transplantation. , 2023, , 177-192.		0
666	Anticoagulant therapy in <sc>COVID</sc>â€19: A narrative review. <i>Clinical and Translational Science</i> , 2023, 16, 1510-1525.	3.1	1
667	Effect of the P-Selectin Inhibitor Crizanlizumab on Survival Free of Organ Support in Patients Hospitalized for COVID-19: A Randomized Controlled Trial. <i>Circulation</i> , 2023, 148, 381-390.	1.6	5
668	Circulating cellular clusters are associated with thrombotic complications and clinical outcomes in COVID-19. <i>IScience</i> , 2023, 26, 107202.	4.1	3
669	Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 Trial. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2023, 43, 1572-1582.	2.4	2
670	Antithrombotic Therapy in Arterial Thrombosis and Thromboembolism in COVID-19. <i>Chest</i> , 2023, 164, 1531-1550.	0.8	2
671	Low molecular weight heparin in COVID-19: benefits and concerns. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	1
672	COVID-19 and Other Viral Infections in Patients With Hematologic Malignancies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2023, , .	3.8	2
673	Effectiveness of early heparin therapy on outcomes in critically ill patients with sepsis-induced coagulopathy. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	6
674	Rivaroxaban to prevent major clinical outcomes in non-hospitalised patients with COVID-19: the CAREâ€COALITION VIII randomised clinical trial. <i>EClinicalMedicine</i> , 2023, 60, 102004.	7.1	4
675	The Evolution and Future of Intensive Care Management in the Era of Telecritical Care and Artificial Intelligence. <i>Current Problems in Cardiology</i> , 2023, 48, 101805.	2.4	2
676	Antithrombotic therapy in the management of hospitalised patients with COVID-19. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2023, 84, 1-11.	0.5	0

#	ARTICLE	IF	CITATIONS
677	Comparison of safety and efficacy between therapeutic or intermediate versus prophylactic anticoagulation for thrombosis in COVID-19 patients: a systematic review and meta-analysis. <i>Acute and Critical Care</i> , 2023, 38, 160-171.	1.4	1
678	Thrombotic complications in children with Coronavirus disease 2019 and Multisystem Inflammatory Syndrome of Childhood. <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 2313-2326.	3.8	5
679	Coronavirus disease 2019 and acute cerebrovascular events: a comprehensive overview. <i>Frontiers in Neurology</i> , 0, 14, .	2.4	1
680	Endothelium dysfunction and thrombosis in COVID-19 with type 2 diabetes. <i>Endocrine</i> , 2023, 82, 15-27.	2.3	2
681	Predictors of pulmonary embolism in hospitalized patients with COVID-19. <i>Thrombosis Journal</i> , 2023, 21, .	2.1	1
682	The Polyanionic Drug Suramin Neutralizes Histones and Prevents Endotheliopathy. <i>Journal of Immunology</i> , 0, , .	0.8	2
683	Initial therapeutic anticoagulation with rivaroxaban compared to prophylactic therapy with heparins in moderate to severe COVID-19: results of the COVID-PREVENT randomized controlled trial. <i>Clinical Research in Cardiology</i> , 2023, 112, 1620-1638.	3.3	2
684	Contemporary outcomes of long-term anticoagulation in COVID-19 patients: a regression matched sensitivity analysis of the national inpatient sample. <i>Expert Review of Cardiovascular Therapy</i> , 0, , 1-8.	1.5	0
685	COVID-19 Patients With Pulmonary Hypertension Hospitalized in the United States During the Early Pandemic: Analysis of In-Hospital Mortality, Clinical Outcomes, and Racial Disparities. <i>Current Problems in Cardiology</i> , 2023, 48, 101933.	2.4	1
686	Quantitative chest CT imaging characteristics and outcome of patients with COVID-19 associated pulmonary artery thrombosis: A single-center retrospective cohort study. <i>Medicine (United States)</i> , 2023, 102, e34250.	1.0	0
687	Thrombosis, major bleeding, and survival in COVID-19 supported by veno-venous extracorporeal membrane oxygenation in the first vs second wave: a multicenter observational study in the United Kingdom. <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 2735-2746.	3.8	4
688	Itâ€™s in the blood: a review of the hematological system in SARS-CoV-2-associated COVID-19. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 0, , 1-30.	6.1	3
689	Post-acute sequelae of COVID-19: understanding and addressing the burden of multisystem manifestations. <i>Lancet Respiratory Medicine</i> , the, 2023, 11, 739-754.	10.7	24
690	Cerebrovascular Disease in COVID-19. <i>Viruses</i> , 2023, 15, 1598.	3.3	1
691	Uncertainties about the roles of anticoagulation and microclots in postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 2697-2701.	3.8	3
692	Coagulation biomarkers and coronavirus disease 2019 phenotyping: a prospective cohort study. <i>Thrombosis Journal</i> , 2023, 21, .	2.1	0
693	Thromboinflammation in acute injury: infections, heatstroke, and trauma. <i>Journal of Thrombosis and Haemostasis</i> , 2024, 22, 7-22.	3.8	8
694	Effect of therapeutic-dose heparin on severe acute kidney injury and death in noncritically ill patients hospitalized for COVID-19: a prespecified secondary analysis of the ACTIV4a and ATTACC randomized trial. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2023, 7, 102167.	2.3	1

#	ARTICLE	IF	CITATIONS
695	Executive summary of the consensus statement of the group for the study of infection in transplantation and other immunocompromised host (GESITRA-IC) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the treatment of SARS-CoV-2 infection in solid organ transplant recipients. <i>Transplantation Reviews</i> , 2023, 37, 100788.	2.9	0
696	The Management of COVID-19-Related Coagulopathy: A Focus on the Challenges of Metabolic and Vascular Diseases. <i>International Journal of Molecular Sciences</i> , 2023, 24, 12782.	4.1	1
697	Are fibrinoid microclots a cause of autoimmunity in Long Covid and other post-infection diseases?. <i>Biochemical Journal</i> , 2023, 480, 1217-1240.	3.7	3
698	Enoxaparin for symptomatic COVID-19 managed in the ambulatory setting: An individual patient level analysis of the OVID and ETHIC trials. <i>Thrombosis Research</i> , 2023, 230, 27-32.	1.7	0
699	Management and Prevention of Venous Thromboembolism in Patients with COVID-19. <i>Current Treatment Options in Cardiovascular Medicine</i> , 0, , .	0.9	0
700	Aptamer-Based Strategies to Address Challenges in COVID-19 Diagnosis and Treatments. <i>Interdisciplinary Perspectives on Infectious Diseases</i> , 2023, 2023, 1-16.	1.4	2
701	Endothelial Dysfunction and Pregnant COVID-19 Patients with Thrombophilia: A Narrative Review. <i>Biomedicines</i> , 2023, 11, 2458.	3.2	0
702	Research Staff COVID-19 Pandemic Survey-Results from the Prevention and Early Treatment of Acute Lung Injury (PETAL) Network. <i>Covid</i> , 2023, 3, 1528-1543.	1.5	0
703	Spectrum of Thrombotic Complications in Fatal Cases of COVID-19: Focus on Pulmonary Artery Thrombosis In Situ. <i>Viruses</i> , 2023, 15, 1681.	3.3	3
704	Comparison of Standard Versus Intermediate Prophylaxis Dose for Venous Thromboembolism Prophylaxis in Patients Hospitalized With COVID-19 Infection. <i>Hospital Pharmacy</i> , 0, , .	1.0	0
705	Effects of inflammation on thrombosis and outcomes in COVID-19: secondary analysis of the ATTACC/ACTIV-4a trial. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2023, 7, 102203.	2.3	0
706	Pathophysiology and targeted treatment of cholesterol crystal embolism and the related thrombotic angiopathy. <i>FASEB Journal</i> , 2023, 37, .	0.5	2
707	Outcomes and characteristics of patients hospitalized for COVID-19 in British Columbia, Ontario and Quebec during the Omicron wave. <i>CMAJ Open</i> , 2023, 11, E672-E683.	2.4	2
708	Bleeding Complications in COVID-19 Critically Ill ARDS Patients Receiving VV-ECMO Therapy. <i>Journal of Clinical Medicine</i> , 2023, 12, 6415.	2.4	0
709	Reply to "Embracing imatinib: a novel approach to safeguarding the endothelial barrier in patients with COVID-19". <i>Angiogenesis</i> , 2023, 26, 485-486.	7.2	0
710	A retrospective multicenter cohort study of the association between anti-Factor Xa values and death, thromboembolism, and bleeding in patients with critical COVID-19. <i>Thrombosis Journal</i> , 2023, 21, .	2.1	0
711	Community Use of Repurposed Drugs Before and During COVID-19 Pandemic in the Netherlands: An Interrupted Time-Series Analysis. <i>Clinical Epidemiology</i> , 0, Volume 15, 923-937.	3.0	0
712	COVID-19 thromboprophylaxis. New evidence. <i>Revista Española De Anestesiología Y Reanimación (English Edition)</i> , 2024, 71, 34-47.	0.1	0

#	ARTICLE	IF	CITATIONS
713	A case report of spontaneous pectoral hematoma in a male with background antiplatelet therapy after severe COVID-19 infection. <i>Thrombosis Journal</i> , 2023, 21, .	2.1	0
714	Treatments for COVID-19. <i>Annual Review of Medicine</i> , 2024, 75, 145-157.	12.2	5
717	Thromboembolic complications after COVID-19 in kidney transplant recipients. <i>Nephrology</i> , 2024, 29, 39-47.	1.6	0
718	Low-molecular-weight heparin for the prevention of clinical worsening in severe non-critically ill COVID-19 patients: a joint analysis of two randomized controlled trials. <i>Internal and Emergency Medicine</i> , 0, , .	2.0	1
720	Venous thromboembolism in an Asian COVID-19 cohort across 3 infection waves—a retrospective observational study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2023, 7, 102218.	2.3	1
721	SARS-CoV-2 infection of human lung epithelial cells induces TMPRSS-mediated acute fibrin deposition. <i>Nature Communications</i> , 2023, 14, .	12.8	0
722	D-dimer trends predict COVID-19 patient's prognosis: A retrospective chart review study. <i>Open Medicine (Poland)</i> , 2023, 18, .	1.3	0
723	Current options of covid-19 management in 2023. <i>Medicina Pro Praxi</i> , 2023, 20, 223-228.	0.0	0
724	Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOV19. <i>BMC Infectious Diseases</i> , 2023, 23, .	2.9	0
725	Simvastatin in Critically Ill Patients with Covid-19. <i>New England Journal of Medicine</i> , 2023, 389, 2341-2354.	27.0	4
726	Intravenous Vitamin C for Patients Hospitalized With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2023, 330, 1745.	7.4	7
727	Predictive Model for Mortality in Severe COVID-19 Patients across the Six Pandemic Waves. <i>Viruses</i> , 2023, 15, 2184.	3.3	4
728	Design and Execution of Clinical Trials in the Cardiac Intensive Care Unit. <i>Critical Care Clinics</i> , 2024, 40, 193-209.	2.6	0
729	Risk factors for thromboembolic events in patients hospitalized for COVID-19 pneumonia in a general ward and requiring treatment with oxygen. <i>Postgraduate Medical Journal</i> , 0, , .	1.8	0
730	Prophylactic Anticoagulation and Thrombosis in Hospitalized Patients with Clinically Stable COVID-19 at Admission: From the Practice-Based Observational Study. <i>Annals of Vascular Diseases</i> , 2023, , .	0.5	0
731	Enoxaparin improves COVID-19 by reducing Neutrophils Extracellular Traps (NETs) production. <i>Clinical Immunology</i> , 2023, 257, 109836.	3.2	1
732	Platelet aggregates detected using quantitative phase imaging associate with COVID-19 severity. <i>Communications Medicine</i> , 2023, 3, .	4.2	0
733	COVID-19 and the Concept of Thrombo-Inflammation: Review of the Relationship between Immune Response, Endothelium and Coagulation. <i>Journal of Clinical Medicine</i> , 2023, 12, 7245.	2.4	2

#	ARTICLE	IF	CITATIONS
734	Rethinking coagulation: from enzymatic cascade and cell-based reactions to a convergent model involving innate immune activation. <i>Blood</i> , 2023, 142, 2133-2145.	1.4	1
735	Platelet Factor 4 Antibodies and Severe AKI. <i>Kidney360</i> , 2023, , .	2.1	1
737	Thromboâ€inflammatory response in hospitalized patients with <scp>COVID</scp>â€19; a single institution experience. <i>Internal Medicine Journal</i> , 0, , .	0.8	0
739	Anticoagulant treatment and COVIDâ€19 mortality among older adults living in nursing homes in Sweden. <i>Health Science Reports</i> , 2023, 6, .	1.5	0
740	COVID-19 and Long-COVID Thrombosis: From Clinical and Basic Science to Therapeutics. <i>Thrombosis and Haemostasis</i> , 2024, 124, 286-296.	3.4	1
741	Therapeutic Heparin in non-ICU patients Hospitalized for COVID-19 in the ACTIV-4a Trial: Effect on 3 Month Symptoms and Quality of Life. <i>Chest</i> , 2023, , .	0.8	0
742	VTE prevention in medical inpatients - Current approach and controversies. <i>Thrombosis Update</i> , 2023, 13, 100151.	0.9	0
743	Acute coronary thrombosis due to heparin-induced thrombocytopenia following improved COVID-19 pneumonia: A case report. <i>Journal of Cardiology Cases</i> , 2023, , .	0.5	1
744	The Impact of High D-Dimer on The Clinical Outcome of Covid-19 patients at A Private Hospital in Jakarta. <i>Research Journal of Pharmacy and Technology</i> , 2023, , 3773-3779.	0.8	0
745	Coronavirus Disease 2019 (COVID-19) and Venous Thromboembolism During Pregnancy and Postpartum. <i>Obstetrics and Gynecology</i> , 2024, 143, 139-142.	2.4	0
746	Whole blood viscoelastic testing profile and mortality in patients hospitalized with acute COVID-19 pneumonia: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2024, 234, 21-31.	1.7	0
747	Thromboelastography-Guided Anticoagulation in Critically Ill COVID-19 Patients: Mortality and Bleeding Outcomes. <i>Journal of Respiration</i> , 2024, 4, 1-11.	1.1	0
749	Clinical trials of pharmacological interventions for SARSâ€CoVâ€2 published in leading medical journals report adherence but not how it was assessed.. <i>British Journal of Clinical Pharmacology</i> , 0, , .	2.4	0
750	COVID-19 und VTE-Prophylaxe. <i>Springer Reference Medizin</i> , 2024, , 1-11.	0.0	0
751	Oral Infections, SARS-CoV-2 Infection, and Autoimmunity. , 2024, , 1013-1044.		0
752	Choice and Duration of Anticoagulation for Venous Thromboembolism. <i>Journal of Clinical Medicine</i> , 2024, 13, 301.	2.4	0
753	Pulmonary embolism impacts clinical outcomes of intubated patients with acute respiratory distress syndrome related to COVID-19. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2024, 43, 101348.	1.4	0
754	The Rise of Adaptive Platform Trials in Critical Care. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2024, 209, 491-496.	5.6	0

#	ARTICLE	IF	CITATIONS
755	Therapeutic-Dose Anticoagulation in Hospitalized Patients With COVID-19. , 2024, 3, 100779.		0
756	Heparin Dose Intensity and Organ Support-Free Days in Patients Hospitalized for COVID-19. , 2024, 3, 100780.		0
757	Fatal attractions that trigger inflammation and drive atherosclerotic disease. European Journal of Clinical Investigation, 2024, 54, .	3.4	0
758	Understanding Heterogeneity in Acute Care Trials: Resource Availability Impacts Outcomes. American Journal of Respiratory and Critical Care Medicine, 2024, 209, 469-471.	5.6	0
759	Effect of antiplatelet therapy after COVID-19 diagnosis: A systematic review with meta-analysis and trial sequential analysis. PLoS ONE, 2024, 19, e0297628.	2.5	0
760	Uncertainties about the roles of anticoagulation and microclots in postacute sequelae of SARS-CoV-2 infection: comment from Kell etÂal.. Journal of Thrombosis and Haemostasis, 2024, 22, 565-568.	3.8	0
761	Uncertainties about the roles of anticoagulation and microclots in post-acute sequelae of SARS-CoV-2 infectionâ€”response to the letter by Kell etÂal.. Journal of Thrombosis and Haemostasis, 2024, 22, 569-571.	3.8	0
762	Pulmonary thrombosis associated with COVIDâ€19 pneumonia: Beyond classical pulmonary thromboembolism. European Journal of Clinical Investigation, 0, , .	3.4	0
763	Transforming research to improve therapies for trauma in the twenty-first century. Critical Care, 2024, 28, .	5.8	0
764	Letter: Anticoagulants in Venous Thrombosis, a Pivotal Risk Factor: Authorsâ€™ Reply. Angiology, 0, , .	1.8	0
765	Tenecteplase With Concomitant Anticoagulation for Acute Respiratory Failure in Patients With COVID-19: A Randomized Controlled Trial. Cureus, 2024, , .	0.5	0
766	Venous thromboembolism prophylaxis in Asian patients with severe COVID-19: A prospective cohort study. Thrombosis Update, 2024, 14, 100162.	0.9	0
767	IL-6 and D-dimer Levels at Admission Predict Cardiac Injury and Early Mortality during SARS-CoV-2 Infection. Cardiovascular Innovations and Applications, 2024, 9, .	0.3	0
768	Exploring the therapeutic role of early heparin administration in ARDS management: a MIMIC-IV database analysis. Journal of Intensive Care, 2024, 12, .	2.9	0
769	COVID-19 and the brain: understanding the pathogenesis and consequences of neurological damage. Molecular Biology Reports, 2024, 51, .	2.3	0
770	The Effect of Antiplatelet Therapy on COVID-19. Juntendo Medical Journal, 2024, 70, 118-120.	0.1	0
771	Early pandemic in-hospital outcomes and mortality risk factors in COVID-19 solid organ transplant patients. Baylor University Medical Center Proceedings, 2024, 37, 414-423.	0.5	0
772	Impact of vaccination on the association of COVID-19 with cardiovascular diseases: An OpenSAFELY cohort study. Nature Communications, 2024, 15, .	12.8	0

#	ARTICLE	IF	CITATIONS
773	Association between loss of hypercoagulable phenotype, clinical features and complement pathway consumption in COVID-19. <i>Frontiers in Immunology</i> , 0, 15, .	4.8	0
774	The Association of Anticoagulation Intensity with Outcomes in Hospitalized COVID-19 Patients. <i>Advances in Hematology</i> , 2024, 2024, 1-9.	1.0	0
775	2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2024, , .	3.8	0
776	Treatment of multisystem inflammatory syndrome in children. <i>World Journal of Pediatrics</i> , 2024, 20, 325-339.	1.8	0
777	Special Issue “COVID-19 Coagulopathy: Advances on Pathophysiology and Therapies” International Journal of Molecular Sciences, 2024, 25, 3548.	4.1	0
778	Small Molecules for the Treatment of Long-COVID-Related Vascular Damage and Abnormal Blood Clotting: A Patent-Based Appraisal. <i>Viruses</i> , 2024, 16, 450.	3.3	0